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Therapeutic angiogenesis aimed at improving peripheral blood flow by 
stimulating the growth and development of collateral vessels has been proposed as a 
potential treatment for peripheral vascular disease. The strategy is based on bio-bypassing 
the under-perfused tissues by inducing the formation of new blood vessels through 
administration of angiogenic growth factors. However, many have relied on single 
angiogenic growth factor protein or its gene administration, which proved to be 
insufficient for the development of a functional vascular system. Synergistic interaction 
between two of these factors  vascular endothelial growth factor (VEGF) and 
angiopoietin-1 (Ang-1) - to produce functional leakage-resistant neovascularization has 
been proposed as a promising and safe candidate for therapeutic angiogenesis. 
Combining the synergistic effect of VEGF165 and Ang-1 together with myoblast (muscle 
precursor cells) therapy for treatment of ischemic limb disease would have the additional 
advantage of inducing myogenesis on top of the commonly reported angiogenesis in 
ischemic limbs.  
In the present study, rabbit autologous primary skeletal myoblasts were used as 
carriers of a novel bicistronic adenoviral vector simultaneously expressing VEGF and 
Ang-1 genes. The cells were prior labeled with retrovirally transduced LacZ reporter 
gene, 4,6-diamidino-2-phenylindole (DAPI) and 5-bromo-2-deoxy-uridine (BrdU) 
before transplanted into a rabbit model of hind limb ischemia. Approximately eight 
weeks after treatment, neovascularization in the limb was assessed by angiography and 
the animals were euthanized and harvested for histological studies. 
viii 
Extensive transplanted skeletal myoblast survival was observed in all cell-
transplanted groups as visualized by DAPI, BrdU and X-gal staining. Angiographic blood 
vessel count revealed enhanced neovascularization in the group that received 
transplantation of myoblasts overexpressing VEGF and Ang-1 as compared to other 
control groups. This was confirmed with immunohistochemical staining for von 
Willebrand Factor-VIII which consistently demonstrated a significant increase in 
capillary density of this group as compared to control groups. 
The study therefore revealed that simultaneous expression of VEGF and Ang-1 
from bicistronic adenoviral vector transduced skeletal myoblasts potently stimulated 
enhanced functional neovascularization in the ischemic limbs.  
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1   INTRODUCTION 
 
1.1 Peripheral vascular disease 
Peripheral vascular disease (PVD) is often caused by atherosclerotic narrowing of 
the arterial lumen. The gradual deposits of lipids, cholesterol, calcium, smooth muscle 
cells and platelets in the atherosclerotic plaque along the artery walls restrict the flow of 
blood, having the most negative impact typically on the legs and feet. The reduction in 
blood flow is often insufficient for supplying oxygen and nutrients to meet the metabolic 
demands of exercising leg muscles, thereby resulting in a condition of leg pain, termed 
intermittent claudication. In severe cases, it can result in critical limb ischemia. By then, 
pain at rest, non-healing wounds and gangrene (dead tissue) are common unavoidable 
consequences. If left untreated, these progressive gangrene, rapidly enlarging wounds or 
continuous ischemic rest pain can be a threat to limb viability. 
Peripheral vascular disease is a common condition with variable morbidity 
affecting mostly population older than 50 years of age. With approximately 5 % having 
intermittent claudication and another 1 % suffering from critical limb ischemia (reviewed 
in Halperin, 2002), it is an increasingly common problem in developed countries, 
including Singapore. 
Currently, therapeutic options to treat PVD include medical therapy, non-surgical 
and surgical interventions. While medications do not eliminate the narrowing of arteries, 
it is prescribed in order to improve blood flow and relieve symptoms. It is used alone or 
in combination with one of the other treatments. To treat plaque accumulation by either 
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removing, compressing or displacing it, non-surgical interventions that involve minimally 
invasive interventional procedures such as angioplasty, sometimes followed by stent 
implantation, atherectomy and thrombolytic therapy provide alternative treatment 
modalities. However, in the case of severe symptoms that do not respond to any of these 
treatment forms, surgical interventions such as bypass surgery may be necessary. This 
involves bypassing the diseased part of the artery by creating new channels to redirect 
blood circulation around the site of the arterial block. Unfortunately, bypass surgery is 
ineffective if the blockage or narrowing in the artery is too extensive, or if the vessel is 
too small, leaving many patients with lower limb amputation as the sole therapeutic 
option. This disease is also associated with significant mortality, with life expectancy in 
30 % of patients being less than two years after their first major amputation. The primary 
cause of mortality in these patients is myocardial infarction, stroke and complications 
from diabetes (Coffman, 1991). Indeed, psychological testing of these patients has 
typically revealed quality-of-life indices similar to those of patients with cancer in critical 
or even terminal phases of their illness (Albers et al., 1992).  
Despite major advances in these areas, PVD is a challenging disease and difficult to 
manage with the current treatment modalities. In some cases, even short-term results in 
treated patients with advanced stage disease remained unsatisfactory. Indeed, there is a 
great clinical need for new treatment options that may stimulate collateral blood vessel 
growth, increase vascularity and improve skeletal muscle function that would 
subsequently translate to substantial improvements in mobility, exercise tolerance, and 
quality of life. 
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1.2 Therapeutic angiogenesis 
Pioneering work of Folkman et al. (1987) and Tomasi et al. (1990) on isolation and 
description of a number of angiogenic growth factors for therapeutic angiogenesis aimed 
at improving peripheral blood flow by stimulating the growth and development of 
collateral vessels, have paved the way for a potentially useful alternative treatment for 
PVD (Fox et al., 1996; Isner et al., 1996a, b; Taniyama et al., 2001; Vale et al., 2001; 
Silvestre and Levy, 2002). The strategy is based on bio-bypassing the under-perfused 
tissues by inducing the formation of new blood vessels (angiogenesis) and has been 
attempted by using various angiogenic growth factors (Hayashi et al., 1999; Gowdak et 
al., 2000a, b; Vincent et al., 2000; Kyriakides et al., 2001; Ohara et al., 2001; Morishita et 
al., 2002; Shimpo et al., 2002). These factors are naturally expressed to initiate the 
growth of collateral vessels in regions where blood flow is limited as a reparative 
mechanism. However, an imbalance between the rapidity and extent of natural 
collateral vessel growth versus the progression of the occlusive arterial disease hinders 
the recovery process. An outside intervention is needed to supplement the inadequate 
intrinsic repair mechanism through the delivery of exogenous angiogenic growth factors 
(Melillo et al., 1997). More recently, implantation of stem cells has been carried out 
together with the delivery of angiogenic growth factors to achieve synergy between the 
two approaches for the treatment of ischemically damaged tissues (Ikenaga et al., 2001; 
Nabel, 2002). Interplay between anti- and pro-angiogenic growth factors is critical for the 
cascade of reactions involved in blood vessel formation and maturation. Indeed, the 
angiogenic process depends on the sequential and cooperative effects of various growth 
factors in order to form functional vessels (Gale and Yancopoulos, 1999). 
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1.2.1 Angiogenesis involves angiogenic growth factors and other stimuli 
 The pivotal role of vascular endothelial growth factor (VEGF) as a potent inducer 
of angiogenesis has been well studied (Ferrara and Henzel, 1989; Ferrara et al., 1991; 
Isner, 1998; Carmeliet and Collen, 1999b; Dvorak et al., 1999; Eriksson and Alitalo, 
1999; Ferrara, 1999; Neufeld et al., 1999). It has direct and specific mitogenic effects on 
endothelial cells (Ferrara and Henzel, 1989). Unlike the other heparin-binding angiogenic 
growth factors, VEGF possesses a typical secretory signal sequence on the amino 
terminus which promotes its release from the intact cells (Leung et al., 1989). The gene 
for human VEGF is organized into eight exons and as a result of alternative splicing, at 
least six transcripts encoding mature monomeric VEGF containing 121, 145, 165, 183, 
189 and 206 amino acid residues (VEGF121, VEGF145, VEGF165, VEGF183, VEGF189, 
VEGF206) have been reported to date (Robinson and Stringer, 2001). VEGF165 binds to 
two high-affinity receptors on the surface of endothelial cells, designated as fms-like 
tyrosine kinase-1 (Flt-1/VEGF-R1) (Shibuya et al., 1990) and kinase insert domain-
containing receptor/fetal liver kinase-1 (KDR/Flk-1/VEGF-R2) (Terman et al., 1992; 
Carmeliet, 1999a). KDR/Flk-1/VEGF-R2 is the principle receptor for VEGF165 and is 
expressed by both endothelial cell progenitors as well as hematopoietic stem cells. 
VEGF165 triggers the angiogenesis cascade by binding to this receptor during 
vasculogenesis in embryonic development to induce the differentiation, proliferation and 
migration of endothelial cells to form the initial network of primitive tubules (Fong et al., 
1995; Shalaby et al., 1995; Carmeliet et al., 1996; Ferrara et al., 1996; Gerber et al., 
1999a, b). 
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Besides VEGF, basic fibroblast growth factor (bFGF) initiates the angiogenesis 
cascade upstream of VEGF by inducing endothelial cells to produce urokinase-type 
plasminogen activator which modifies the extracellular matrix to allow subsequent 
invasion of the activated capillary endothelial cells (Montesano et al., 1986). With 
promising data from animal studies, bFGF has been employed in clinical trials (Lazarous 
et al., 2000; Lederman et al., 2002).  
The role of Ang-1 is crucial for further remodeling and maturation of the initially 
immature vasculature. Ang-1 exists predominantly as a homo-multimer, held together by 
coiled-coil domains and disulfide cross-links and signals through a receptor-like tyrosine 
kinase Tie2/Tek. These receptors are expressed specifically on endothelial cells and early 
hematopoietic cells (Iwama et al., 1993; Sato et al., 1993; Korhonen et al., 1994; Sato et 
al., 1995; Davis et al., 1996; Procopio et al., 1999; Huang et al., 2000). Mesenchymal 
cells first express Ang-1 that in turn activates the Tie2 receptor on the endothelial cells to 
produce and release a recruiting signal. This recruiting signal would in turn induce the 
differentiation of the mesenchymal cells into peri-endothelial support cells such as 
pericytes and smooth muscle cells (Rohovsky et al., 1996). Interaction between the 
endothelial cells and the surrounding support cells to form a mature vessel wall will then 
solidify and stabilize the newly formed blood vessel (Davis et al., 1996; Suri et al., 1996). 
Following vessel maturation, Ang-1 continues to play an important role in maintaining 
the stability of the mature vasculature. In the absence of maturation factors such as Ang-1, 
VEGF stimulates vascular permeability in the small immature blood vessels, composed 
merely of the endothelial cell lining. The increased permeability causes leakage of 
plasma proteins, with resultant hemangioma formation. In vitro experiments have also 
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shown that Ang-1 potently induces chemotactic response (Witzenbichler et al., 1998), 
network formation (Papapetropoulos et al., 1999), sprouting (Koblizek et al., 1998; Kim 
et al., 2000a) and survival in apoptosis (Papapetropoulos et al., 1999; Kim et al., 2000b) 
but has no mitotic effect (Davis et al., 1996; Kim et al., 1999). Hence, although Ang-1 is 
incapable of mediating endothelial cell growth or tubule formation as VEGF, it seems to 
play a role in later stages of vessel development.  
Another important member of the angiopoietin family is angiopoietin-2 (Ang-2), 
which blocks the constitutive stabilizing action of Ang-1 (Maisonpierre et al., 1997; 
Goede et al., 1998). This occurs when Ang-2 competes with Ang-1 for the Tie2 receptor 
resulting in the inhibition of the Ang-1/Tie2 signal. Such an event results in a loosening 
of the tight vascular structure that has been maintained previously by the Ang-1/Tie2 
signal. Thus, this leads to the opening up of the vessel structure to allow protease 
degradation of the basement membrane surrounding the endothelium. The exposed 
endothelial cells are now easily accessed by angiogenesis inducers such as VEGF. If 
VEGF is indeed present, the endothelial cells become activated to migrate and proliferate, 
thereby producing new capillary sprouts and in turn tubes in a process termed 'angiogenic 
sprouting'. Such sprouting event is followed by a shift in the local balance of Ang-1/Ang-
2 back in favor of Ang-1 to allow maturation and stabilization of the newly formed vessel. 
In addition to the above-mentioned factors, many other proangiogenic factors 
influence the angiogenic process, amongst which are members of the transforming 
growth-factor β-family, epidermal growth factor, tumor necrosis factor-α, platelet-
derived growth factor BB, hepatocyte growth factor, interleukin-1a and nitric oxide, 
whose roles include stimulating VEGF expression as well as stabilization of newly 
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formed blood vessels. (Murohara et al., 1998; Hellstrom et al., 1999; Hirschi et al., 1999; 
Carmeliet, 2000a; Onimaru et al., 2002). Furthermore, a myriad of other gene products, 
ranging from transcription factors to members of the Notch family, also play crucial role 
in vessel formation (Carmeliet, 2000a).  
 On top of these, angiogenesis is also strongly regulated by hypoxia (Semenza, 
1999) and metabolic stimuli such as hypoglycemia and acidosis. There is evidence that 
hypoxia upregulates transcription of VEGF mRNA and the vessel stability is enhanced in 
terms of increased vascular smooth muscle cells due to stimulation by the hypoxia-
inducible factor-1 (HIF-1). In rats chronically exposed to hypoxic condition, the mRNA 
for both VEGF and KDR/Flk-1/VEGF-R2 is upregulated in the lung tissue (Tuder et al., 
1995). Hence, hypoxia is a major driving force for angiogenesis (Plate et al., 1992; 













1.2.2 Delivery strategies for therapeutic angiogenesis 
For therapeutic angiogenesis, angiogenic growth factors have been administered 
either as recombinant proteins or by way of gene transfer (Table-1).  
 
Table-1: VEGF protein/gene transfer in animal model of limb ischemia 
 
Delivery technique   Animal model Reference 
Recombinant protein  Rabbit   Bauters et al., 1994, 1995 
   Rabbit   Takeshita et al., 1994a, b, 1995 
Rabbit   Hopkins et al., 1998 
Rat    Chang et al., 2003 
 
Naked plasmid DNA Rabbit/Rat  Takeshita et al., 1996/1998 
Rabbit   Chae et al., 2000 
Rabbit   Shyu et al., 2003a 
 
Adenoviral vector   Rabbit   Hershey et al., 2003 
 
Adeno-associated virus  Rat    Arsic et al., 2003 
 
Liposome   Rabbit   Gowdak et al., 2000a 
 Rat   Neumeister et al., 2001 
 
 
However, because of limited availability of human-quality grade recombinant 
protein and the cost effectiveness of the procedure, the feasibility of using recombinant 
angiogenic growth factor proteins is currently limited. On the contrary though, gene 
transfer strategy makes use of the gene encoding for the growth factor to be administered 
as a template for production of the therapeutic protein. Such therapeutic strategy 
harnesses the patients own cellular machinery to produce the growth factors rather than 
relying on pharmacotherapy. The cells transduced with the exogenous gene serve as 
reservoirs for the growth factor protein for a certain period of time (Leiden, 2000) and as 
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such avoids repeated dose administration (Takeshita et al., 1994a). The angiogenic gene 
can be delivered as a naked plasmid DNA or carried in a vector cassette (Takeshita et 
al., 1996; Tsurumi et al., 1996). The delivery has been achieved via a variety of 
approaches, such as direct injection and electroporation (Takeshita et al., 1996; Tsurumi 
et al., 1997; Takeshita et al., 1998). Intravenous administration of naked plasmid DNA 
does not elicit an autoimmune response (Nabel et al., 1992) as double stranded DNA is 
minimally antigenic because the bases are in essence shielded from immunologic 
surveillance by the double helices (Schwartz and Stollar, 1985). The delivery of naked 
plasmid DNA however, suffers the drawback of low transfection efficiency. This is most 
likely connected to the large molecular size of the plasmid (13-15 kb) which account for 
the poor uptake by cells. To overcome the problem of transfection efficiency, vector-
mediated gene transfer using viral as well as non-viral vectors, have thus been designed 
to effect therapeutic angiogenesis (Roessler et al., 1994; Schwartz et al., 1995; Goldman 
et al., 1997). The viral vectors including replication-deficient adenovirus, retrovirus, 
lentivirus, and adeno-associated virus, are often efficiently taken up by the host cells via 
receptor-mediated mechanisms or endocytosis upon their delivery to the target tissue 
(Table-2). Of these, adenoviruses (Ad) have been widely used for gene therapy, due to 
their ability to efficiently transduce non-dividing cells (Gilgenkrantz et al., 1995; 
Muhlhauser et al., 1996; Crystal, 1997). Moreover, adenoviral vectors may be amplified 
and produced to high titres (1011  1013 virus particle ml-1) besides being capable of 
infecting post-mitotic cells and accommodating transgene cassette of up to 10 kb. They 
are made replication deficient by producing point mutations, deletions, insertions and 
combinations directed toward a specific adenovirus gene(s), such as the early region 1 
10 
(E1) gene. Unfortunately, the use of viral vector-based gene delivery has remained 
questionable due to its serious immunologic concerns. Adverse reactions from incomplete 
inactivation of the viral replication machinery lead to life-threatening systemic 
inflammatory-like reactions (Leiden, 2000; Verma, 2000). In addition, administration of 
adenoviral vectors immediately after induction of acute ischemia in rat hind limbs cause 
inflammation and subsequent limb gangrene that seemed to be aggravated by the 
adenovirus capsid protein (Brevetti et al., 2001).  Pioneering work of Felgner et al. (1987) 
introduced lipofection for non-viral gene transfer. The winning characteristics of 
lipofection are its low cytotoxicity, low immunogenicity and non-integration into host 
genome. Once again though, lipofection suffers the drawback of low transfection 







































































































































































































































































































































































































   



































1.2.3 Therapeutic angiogenesis using VEGF 
Despite numerous investigations, the challenge remains in identifying the factor 
or combination of factors that will stimulate functional neovascularization. VEGF was 
previously perceived to fit this criterion. Various animal studies have shown 
augmentation of the collateral blood flow and function in hind limb ischemia models 
(Takeshita et al., 1994a, b; Walder et al., 1996; Baffour et al., 2000; Cherng et al., 2000). 
However, recent reports on the use of VEGF for therapeutic angiogenesis in PVD 
treatment have revealed untoward effects of the therapy (Baumgartner, 2000; Masaki et 
al., 2002). Overexpression of VEGF results in the formation of non-functional leaky 
vessels in experimental animals, while plasmid-based intramuscular VEGF gene transfer 
has led to transient edema in human subjects (Baumgartner et al., 1998; Schainfeld et al., 
1999; Thurston et al., 1999, 2000). Other undesirable effects of VEGF include formation 
of angioma-like fragile capillary network without connections with the pre-existing 
vessels (Springer et al., 1998; Carmeliet, 2000a; Lee et al., 2000). This was further 
confirmed by Masaki et al. (2002) who showed that VEGF gene transfer to limbs led to 
an accelerated amputation associated with massive muscular edema, necrosis and 
disturbed regeneration. The study also observed no significant increase in blood perfusion 
though increased number of capillaries was apparent. This latter notion was consistent 
with a report from Hershey and colleagues (2003) who demonstrated that VEGF gene 
transfer to limbs led to a robust increase in capillary density. However, there was no 
significant improvement in the collateral blood flow. Taken together, these findings 
showed that VEGF overexpression stimulated sprouting of immature leaky blood 
conduits that lack encasement with vascular smooth muscle cells. In a follow-up study, 
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Ozawa et al. (2004) demonstrated a discrete threshold level in VEGF dosage (~70ng/106 
cells/day), below which normal, non-leaky, stable capillaries are induced and above 
which hemangioma growth occurs. The study used a clonal population of myoblasts 
(muscle precursor cells) carrying a retrovirally transduced VEGF gene. This homogenous 
population of genetically modified myoblasts allows constitutively long-term VEGF gene 
expression at precisely controlled low dosage. Under these conditions, VEGF remarkably 
promoted growth of stable, non-leaky capillaries of uniform size independent of 
continued VEGF expression. Thus, long-term continuous delivery of VEGF, when 
maintained below a threshold microenvironmental level, can lead to normal angiogenesis 
without other exogenous growth factors. On the other hand, overexpression of VEGF 
above this threshold level, without the accompaniment of maturation factors such as Ang-
1, leads to aberrant angiogenesis. This showed that uncontrolled and imbalance of 
angiogenic signals may have deleterious effects and may not always contribute to the 
formation of functional neovascularization.  
 
1.2.4 Therapeutic angiogenesis using FGF 
Besides VEGF, members of the FGF family have also been widely used for 
therapeutic angiogenesis. In a study by Baffour et al. (1992), bFGF was administered 
intramuscularly to rabbits with acute hind limb ischemia. Upon completion of treatment 
at 14 d, angiography and necropsy measurement of capillary density showed evidence of 
augmented collateral vessel formation in the lower limb compared with controls. It has 
also been reported that bFGF accelerates wound healing in several animal models 
(McGee et al., 1988; Mooney et al., 1990). Surprisingly though, a comparison between 
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Ad-FGF-4 and Ad-VEGF by Rissanen et al. (2003), revealed that intramuscular injection 
of both these vectors resulted not only an increased in collateral growth, popliteal blood 
flow and muscle perfusion, but also demonstrated the side effect of vascular permeability 
and edema in transduced muscles of rabbit hind limb ischemia. FGF-4 is capable of 
inducing vascular permeability, therapeutic angiogenesis and arteriogenesis comparable 
to that of VEGF. The underlying reason to this similarity may be related to FGF-4 
mediated upregulation of endogenous VEGF level, which may in part explains the effects 
thought to be VEGF specific.  
 
1.2.5 Therapeutic angiogenesis using nitric oxide synthase 
Previously thought of as a noxious gas, nitric oxide (NO) is now recognized as an 
important mediator of vascular responsiveness. It is synthesized in the vascular 
endothelium utilizing the enzyme nitric oxide synthase (NOS) and diffuses in the 
adjacent vascular media, where it has a vasodilatory action (Palmer et al., 1987). 
The role of nitric oxide in vasodilatation makes it an attractive candidate for 
angiogenic therapy. This is supported in a recent study by Brevetti et al. (2003) who 
demonstrated that adenoviral overexpression of NOS in a rat model of hind limb 
ischemia increased blood flow and tissue oxygenation to the limb without a significant 






1.2.6 The approach to achieve angiogenic synergy  
Considering that angiogenesis involves interplay between various growth factors 
and effector cells, which is very delicately poised to favor the formation of new blood 
vessels, simultaneous delivery of multiple angiogenic factors may lead to better prognosis. 
Indeed, the approach of using a combination of factors to achieve angiogenic synergy has 
shown more promise for the treatment of PVD. Asahara and colleagues (1995) 
investigated the simultaneous delivery of VEGF and FGF to achieve angiogenic synergy. 
In a rabbit model of hind limb ischemia, significantly greater capillary density was 
achieved in experimental animals receiving both VEGF and bFGF as compared to the 
ones receiving VEGF or bFGF alone. Furthermore, there was progressive increase in the 
luminal diameter in the experimental group. This was confirmed in a similar study by 
Kondoh et al. (2004) who reported that combined gene delivery of VEGF and bFGF 
produced additive or synergistic effects of collateral development as compared to those 
receiving either gene alone.  Cao et al. (2003) combined FGF-2 and platelet-derived 
growth factor (PDGF)-BB to synergistically induce vascular networks. The results 
revealed that simultaneous administration of both factors stimulated functionally stable 
arteriogenesis with significantly improved blood flow.  
A comparative study between VEGF and FGF-2 gene therapy revealed that FGF-
2 gene therapy alone was effective to treat hind limb ischemia with no deleterious effects 
(Masaki et al., 2002). Apparently, the underlying mechanism of repair was the concerted 
action of FGF-2 and VEGF after FGF-2 gene administration which strongly evoked 
endogenous VEGF expression. The duo combination of these factors led to functionally 
mature neovascularization with a positive smooth muscle actin coating. More 
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interestingly, FGF-2 acts as a muscle regenerating factor and hence, FGF-2 gene transfer 
not only induced the angiogenesis cascade but also induced muscle regeneration 
(Lefaucheur et al., 1995; Lefaucheur et al., 1996). 
In another study using systemic delivery of Ang-1 gene by adenoviral vector, 
angiogenic synergy between VEGF and Ang-1 reduced vascular leakage induced by 
mustard oil and VEGF in adult vessels (Thurston et al., 2000). Thus, it appears that 
VEGF administration, together with Ang-1 seemingly stabilizes the neovasculature. More 
importantly, combining transgenic Ang-1 and VEGF had an additive effect on 
neovascularization and produced the leakage-resistant vessels typical of Ang-1 
overexpression (Thurston et al., 1999; Arsic et al., 2003; Shyu et al., 2003a). These 
findings were further confirmed by Chae et al. (2000) who combined VEGF and Ang-1 
gene delivery to rabbit ischemic hind limb for enhanced effect on blood flow and 
capillary formation. Thus, combined growth factor administration seems to be an 
important requisite in therapeutic terms and this raises the suitability of VEGF and Ang-1 










1.2.7 VEGF and Ang-1 synergy: an ideal combination for therapeutic angiogenesis 
Despite achieving significant improvements in collateral development through 
administration of various angiogenic growth factors and other stimuli in experimental 
animal models, it is still premature to gauge if the exciting results obtained in animals can 
be recapitulated in humans. No doubt the proof of concept studies in these animal 
models (Table-4) have revealed the safety and feasibility of therapeutic angiogenesis for 
the treatment of PVD and have now formed the basis of various human clinical trials 
(Table-3). Indeed, VEGF (Isner et al., 1996a, b; Baumgartner et al., 1998; Makinen et al., 
2002; Shyu et al., 2003b) and bFGF (Lazarous et al., 2000; Cooper et al., 2001; 
Lederman et al., 2002) have gone one step further by being used in Phase I and II clinical 
trials as well. However, results have been rather conflicting with respect to the 
demonstration of a salutary biologic effect. Clearly, further studies are needed to 
elucidate the mechanism involved in successful therapeutic angiogenesis. 
 
Table-3: Growth factor used for therapeutic angiogenesis in clinical phase I and II 
studies of lower limb ischemia 
 
Growth factor  Reference 
 
VEGF Isner et al., 1996a, b; Baumgartner et al., 1998; Makinen et 
al., 2002; Shyu et al., 2003b. 
 











Table-4: Growth factor(s) used for therapeutic angiogenesis in animal models of limb 
ischemia 
 
Growth factor  Reference 
 
VEGF Bauters et al., 1994, 1995; Takeshita et al., 1994a, b, 1995, 
1996, 1998; Walder et al., 1996; Hopkins et al., 1998; 
Cherng et al., 2000; Gowdak et al., 2000a, b; Lu et al., 
2001; Neumeister et al., 2001; Smythe et al., 2002; Chang 
et al., 2003; Hershey et al., 2003. 
 
VEGF and Ang-1 Chae et al., 2000; Arsic et al., 2003; Shyu et al., 2003a 
 
VEGF and bFGF Asahara et al., 1995; Kondoh et al., 2004 
 
bFGF Baffour et al., 1992; Chleboun et al., 1992; Chleboun and 
Martins, 1994; Yang et al., 1996, 2000 
 
aFGF Tabata et al., 1997 
 
FGF-2  Masaki et al., 2002 
 
FGF- 4 Rissanen et al., 2003 
 
PDGF-BB & FGF-2 Cao et al., 2003  
 
ECGF Pu et al., 1993 
 
PAR-2AP  Milia et al., 2002 
 
 
PDGF= Platelet-derived growth factor  
ECGF= Endothelial cell growth factor 
PAR-2AP= Protease activated receptor-2 activating peptide 
 
Having taken into consideration these previous studies, we believe that synergistic 
interaction between VEGF and Ang-1 is the right combination for effective therapeutic 
vascularization in the treatment of limb ischemia. This is partially because they 
contribute to a combined beneficial effect of what the other angiogenic growth factors 
and stimuli have to offer. For instance, VEGF can also stimulate vasodilatation 
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(Takeshita et al., 1998) by acting upstream of the NO pathway. Apparently, VEGF binds 
to its VEGF-R2 receptor found on endothelial cells to stimulate production of NOS that is 
in turn responsible for synthesis of NO (Kroll and Waltenberger, 1998). The direct use of 
NO for treatment of ischemic limb can improve blood flow through vasodilatation 
(Brevetti et al., 2003), however one must be cautious of the other effects that NO has on 
other systems of the body. Nitric oxide also inhibits the aggregation of platelets and thus 
keeps inappropriate clotting from interfering with blood flow. Overexpression of NO may 
instead cause unwanted continuous bleeding. Moreover, some motor neurons of the 
parasympathetic branch of the autonomic nervous system release NO as their 
neurotransmitter and their overexpression may thus produce unwanted continuous 
activation of a particular neuronal pathway. Using VEGF, on the other hand, provides a 
safer option as its main role is limited to the vascular system. The effects of VEGF-
mediated synthesis of NO would be less direct and thus most probably limited to 
vasodilatation.  
 Besides, VEGF overexpression in the accompaniment of a maturation factor like 
Ang-1, plays a major role in formation of functional new blood vessels. VEGF plays the 
pivotal role by inducing the differentiation, proliferation and migration of endothelial 
cells to form the initial network of primitive tubules. Ang-1 influences the remodeling 
and maturation of this initially immature vasculature by recruiting support cells such as 
pericytes and smooth muscle cells to form mature and stable newly formed blood vessels. 
Following vessel maturation, Ang-1 continues to play an important role in maintaining 
the stability of the mature vasculature. In the absence of maturation factor, VEGF 
stimulates vascular permeability in the small immature blood vessels that are merely 
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blood vessel conduits. The increased permeability causes leakage of plasma proteins, 
with resultant hemangioma formation, thereby emphasizing the need for both growth 
factors.  
 Whilst FGF has also been reported to activate the angiogenic cascade by 
stimulating VEGF expression, VEGF may still be the preferred choice for treatment of 
ischemic limb. FGF, unlike VEGF, lacks a secretory signal sequence and is therefore not 
actively secreted from cells following gene transfer (Tabata et al., 1997). It is therefore a 
necessity that FGF gene be modified by adding a signal sequence prior to transfection in 
order to achieve a clinical response. This added difficulty has caused less interest in 
developing gene transfer methods for FGF compared with VEGF. In addition, though 
FGF is a powerful mitogen of the endothelial cells, it is not endothelial cell specific like 
the other angiogenic growth factors such as VEGF and Ang-1. This choice of VEGF over 
FGF is further supported in a comparative study between VEGF and FGF-2 by Palmer-
Kazen et al. (2004). The outcome of the study indicated that there are elevated 
concentrations of FGF-2 in calf muscle, whereas VEGF concentrations do not appear to 
be higher in the ischemic part of the leg in patients with critical limb ischemia. These 
findings suggest that VEGF supplementation may be a more appropriate strategy for 
therapeutic angiogenesis to the calf area for critical limb ischemia than FGF-2.  
 
1.3 Cell transplantation for angiogenesis 
Despite encouraging results from direct protein or gene transfer of angiogenic 
growth factors, the approach is still fraught with problems including neoplasms and 
plaque angiogenesis. With the view to overcome these problems, the focus is now 
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shifting to combo-therapy involving cell transplantation together with therapeutic 
angiogenesis (Hamano et al., 2001; Ikenaga et al., 2001). The angiogenic effect induced 
by implantation of of various cells with intrinsic ability to express various growth factors 
or genetically modulated to express angiogenic factors have recently been examined. 
Bone marrow cell implantation is a safe and effective choice for the treatment of 
ischemic limb disease (Hirakata et al., 2003). Al-Khaldi and colleagues (2003) showed 
that autologous marrow stromal cells implantation induced a neovascular response 
associated with significant increase in blood flow to rat ischemic limbs. Similar results 
have been documented by implantation of peripheral blood mononuclear cells and 
platelets into ischemic limbs of athymic nude rats to induce collateral vessels (Iba et al., 
2002). 
 
1.4 Ex vivo gene therapy for therapeutic angiogenesis 
The approach of combo-therapy for therapeutic angiogenesis is gaining popularity 
and involves removing cells from the body to genetically modulate them with the 
angiogenic growth factor genes in culture before introducing them back into the host 
(Suzuki et al., 2001; Iwaguro et al., 2002; Haider et al., 2004). The genetically modulated 
cells become integrated into the host tissue to provide a sustained and localized elevation 
in the growth factor level. The duration of gene expression is determined by the vector 
which has been used for gene transfer into the cells. For instance, whilst retroviral vectors 
allow stable integration of the exogenous genes into the host cell genome, adenoviral 
vectors merely remain outside of the host genome as an episome. As such, retroviral-
mediated gene transfer allows long-term stable expression of the angiogenic growth 
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factors wherelse its adenoviral counterpart allows only transient expression of the factor. 
The genetically altered cells can be fully characterized in vitro before transplantation to 
ensure expression of the recombinant products. Moreover, the isolated cells generally 
avoid inadvertent transduction of cells other than the target cells. By contrast, direct 
intramuscular naked plasmid DNA injection, viral-mediated gene delivery or other 
vector-mediated gene delivery are often limited by the variable transduction efficiency, 
thus making secretion levels difficult to predict. Furthermore, problematic immunological 
effects associated with most other methods can be avoided with ex vivo approaches by 
transplantation of autologous cells. The choice of cell suitable as a vector for delivery of 
the growth factor gene however, remains a debatable issue. Skeletal myoblast appears to 
be most suitable due to their superior characteristics (Table-5).  
 
 Table-5: Advantages of skeletal myoblasts for cell transplantation 
 
 
• Established protocols for the isolation and expansion of primary skeletal 
myoblasts from animal and human skeletal muscles. 
• High growth potential in vitro and easy maintenance in culture over a longer 
period of time by passaging. 
• Easy to genetically manipulate in vitro and extensively characterized before re-
implantation back into muscle. 
• Ability to fuse with pre-existing muscle fibers upon intramuscular transplantation. 
• Strong resistance to ischemia in vivo. 
• No tumorigenic and toxicity issues after transplantation. 







1.4.1 Skeletal myoblasts participate in myogenesis 
During myogenesis, mononucleated muscle precursor cells called myoblasts, fuse 
with one another. The fusion process is preceded by a complex series of sequential events 
including cell alignment, adhesion and intercellular communication. The fusion event 
itself is rather peculiar as it does not involve breakdown of nuclear membrane. Rather, 
the nuclei of the fusing cells remain as independent discrete units and perform their 
function independently. They form multinucleated myotubes that share a common pool of 
genetic material. Each myotube contains centrally located nuclei which are arranged in 
linear order. Upon establishing the neuronal and vascular connections, these myotubes 
undergo further differentiation into myofibrils and thence into the mature fully functional 
muscle fibers. In the event that these myotubes fail to develop any such connections, they 
simply degenerate. 
As these muscle fibers are terminally differentiated tissues, they are no longer 
capable of undergoing mitosis for maintenance purpose. Rather, muscle fibers are 
maintained by a unique resident population of mononuclear myogenic precursors called 
the satellite cells. These cells, which take residence between the sarcolemma and the 
basal lamina of the muscle fibers, account for only approximately 5 % of the total nuclei 
present within muscle fibers (Bischoff, 1994). They divide at a slow rate to sustain both 
self-renewal and growth of differentiated tissue. However, in response to muscle injury or 
in individuals inflicted with chronic degenerative myopathies, satellite cells migrate to 
sites of muscle fiber damage and divide extensively in order to produce sufficient 
mononuclear myoblasts that later fuse with each other and also with the ends of damaged 
myofibers to repair and repopulate the traumatized muscle. Unfortunately, the self-
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renewal potential of adult satellite cells is limited, decreases with age and can be 
exhausted by a chronic regenerative process such as that characteristic of severe muscular 
dystrophies.  
Besides satellite cells, recent studies have suggested that stem cells from sources 
other than muscle, could contribute to muscle regeneration. Indeed, this was supported by 
evidence that progenitor cells isolated from bone marrow (Ferrari et al., 1998; Gussoni et 
al., 1999), the embryonic vasculature (De Angelis et al., 1999), the neuronal compartment 
(Clarke et al., 2000; Galli et al., 2000), and various mesenchymal tissues (Young et al., 
2001 a, b) can also differentiate into the myogenic lineage.  
 
1.4.2 Skeletal myoblasts as carriers of exogenous genes 
Beyond their role in myogenesis and muscle repair, normal skeletal myoblasts 
have been isolated, cultured and transplanted in vivo to treat a variety of diseases. 
Although the number of satellite cells in adult skeletal muscle is low (only about 5 %), 
protocols have been established for the isolation and expansion of primary skeletal 
myoblasts from both animal and human skeletal muscles (Rando et al., 1994). Hence, it is 
technically feasible to isolate and propagate sufficient numbers of skeletal myoblasts to 
augment muscle function in vivo. The role of skeletal myoblasts as carriers of exogenous 










Table-6: Studies on myoblast-mediated gene therapy. 
 
Gene delivered  Cell source Animal model  Reference 
 
HGH   PMM  Mouse   Barr et al., 1991;     
Dhawan et al., 1991 
 
CF-IX    PMM  Mouse   Dai et al., 1992 
   C2C12  Mouse   Yao et al., 1992 
   PMM   Mouse   Yao et al., 1994 
 
Erythropoietin  C2C12  Mouse   Hamamori et al., 1994,1995 
PMM    Mouse   Bohl et al., 1997 
 
 
C2C12= A myogenic cell line; CF= Coagulation factor; HGH= Human growth hormone 
PMM= Primary mouse myoblast 
 
Springer et al. (1998) have made use of the duo myoblast and VEGF gene 
combination for transplantation into the non-ischemic muscles of immunodeficient SCID 
mice. However, due to retroviral transduction of myoblasts, there was long-term stable 
expression of the angiogenic growth factor. Consequently, the constitutive 
overexpression of VEGF after implantation led to an increased in vascular structures and 
hemangioma formation. The deleterious effect of retroviral transduction is also 
highlighted in a recent report that showed retrovirally transduced human cells have the 
potential of causing malignant transformation (Hacein-Bey-Abina et al., 2003). To 
overcome this problem, a tetracycline-inducible system has been developed that permits 
interruption of the expression of the gene after a given period or to switch it on at a 
desired time point (Kringstein et al., 1998; Blau and Rossi, 1999). The ability to control 
the expression of the VEGF gene by using regulatable promoters is indeed a significant 
development. The differential expression of the gene alone gave rise to very different 
vessel phenotypes as reported in a recent study by Springer et al. (2003). Apparently, in 
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areas adjacent to the implantation site of the VEGF-producing myoblasts, the typical 
pattern of the capillary network in skeletal muscle was replaced by numerous smooth-
muscle-cell-coated vessels. Similar phenotypes were also observed in areas of reduced 
myoblast engraftment. Lu et al. (2001) delivered recombinant VEGF to mouse ischemic 
hind limbs using implantable bioartificial muscle tissues made from retrovirally 
transduced VEGF-expressing mouse primary skeletal myoblasts. The outcome was a 2- 
to 3-fold increase in capillary density with no evidence of hemangioma formation. Based 
on these findings and encouraging experimental evidence, angiomyogenesis using 
myoblasts transduced with angiogenic growth factor genes offers an attractive potential 
option for treatment of PVD.  
 
1.4.3 Pitfalls in myoblast transplantation for gene delivery 
One of the basic requirements of any cell-based therapy is that it requires an 
effective dispersion of the cells from the site of injection. In the case of myoblast 
transplantation, various strategies have been adopted to promote the migration of donor 
myoblasts through the interstitial connective tissue into host muscle. In order to facilitate 
such migration, enzymes have been used to degrade the extracellular matrix in the host 
muscle (Ito et al., 1998; Caron et al., 1999; El Fahime et al., 2000; Torrente et al., 2000). 
Alternatively, multiple injection site delivery approach has been adopted to facilitate 
donor cell dispersal. However, the damaging effect of these methods on the host tissue 
may limit their clinical relevance. More attractive and clinically viable alternatives 
include enhancement of their proliferation and delaying their fusion through genetic 
modulation or the administration of exogenous myoblasts mitogens. Skeletal myoblasts 
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grown with 20 µg/mL of Concanavalin-A two days before transplantation into mice 
skeletal muscles showed increased migration from the injection site (Ito et al., 1998). 
Similarly, absence of the myogenic regulatory gene MyoD in donor skeletal myoblasts 
significantly enhances their migration into host muscle from sliced muscle graft, 
however, with as yet unknown mechanism (Smythe and Grounds, 2001a).  
Another problem associated with myoblast transplantation is the onset of rapid 
and massive death of grafted cells observed after the transplantation (Beauchamp et al., 
1994; Huard et al., 1994a). Besides other factors, the host immune response has been 
implicated in the rapid and massive death of the donor cells (Smythe et al., 2000b). The 
use of immunosuppression has led to the long-term survival of grafts of muscle and 
myoblasts (Kinoshita et al., 1994, 1996a; Lochmuller et al., 1996). More interesting 
though, are studies that reported a significantly higher number and better persistence of 
dystrophin-positive myofibers demonstrated when the injected muscle and donor 
myoblasts expressed a similar myosin heavy chain (MyHC) in comparison with 
myoblasts transfer between host muscle and donor myoblasts that were not matched for 
MyHC (Qu et al., 2000). These results suggest that careful matching between the injected 
myoblasts and injected muscle for the MyHC expression can improved the efficiency of 
myoblasts-mediated transfer to skeletal muscle. There is compelling evidence that 
skeletal myoblasts grown with 100 ng/mL bFGF exhibit reduced myotube formation in 
vitro and higher level of survival in vivo as compared to those cultured without bFGF 
(Kinoshita et al., 1995, 1996b). Morevoer, the problem of massive cell death is currently 
being compensated by injection of a larger number of donor cells. 
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In summary, combo-therapy involving skeletal myoblasts and therapeutic 
angiogenesis offers a promising avenue for treatment of ischemic limb disease. Ex vivo 
angiogenic growth factor gene delivery by myoblast-mediated transfer offers a potential 
therapeutic option for limb ischemia. The outcome of the procedure may be improvised 
through angiogenic synergy by using a bicistronic vector. 
 
1.5 Statement of problem and hypotheses 
1.5.1 Project aim 
The idea of combining myogenesis and angiogenic synergy through the use of a 
combination of angiogenic factors is interesting. As mentioned previously, single growth 
factor gene delivery into ischemic animal models is insufficient for therapeutic purposes. 
In fact, there is clear evidence now, as shown in studies of animals and human patients, 
that delivery of a single angiogenic agent can cause serious complications (Carmeliet, 
2000b; Lee et al., 2000; Celletti et al., 2001; Epstein et al., 2001). Indeed, the 
development of a functional vascular system requires more than a single growth factor, 
their receptors and intracellular signals (Folkman and D'Amore, 1996; Risau, 1997; 
Carmeliet, 2000a).  
The use of skeletal myoblasts as carriers of various exogenous genes has been 
widely studied in experimental animal models (Barr and Leiden, 1991; Dhawan et al., 
1991; Dai et al., 1992; Yao and Kurachi, 1992; Yao et al., 1994; Hamamori et al., 
1994,1995; Bohl et al., 1997). However, its use as a vehicle for angiogenic genes such as 
VEGF is currently limited to studies focusing on experimental heart failure models 
(Taylor et al., 1998; Scorsin et al., 2000; Suzuki et al., 2000) but not that of ischemically 
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damaged hind limbs. It was therefore the primary aim of the present research to 
investigate the feasibility and efficiency of transplanting autologous skeletal myoblasts 
transiently expressing VEGF165 and Ang-1 genes to treat hind limb ischemia.  
 
1.5.2 The bicistronic adenoviral vector construct 
A novel adenoviral bicistronic vector encoding for the human VEGF165 and 
human Ang-1 genes under the control of the same promoter was used to transduce these 
myoblasts. This vector was constructed in Dr Ge Ruowen, Angiogenesis Laboratory, 
National University of Singapore. A plasmid-based system approach similar to that 
reported by Bett et al. (1994) was used to insert the foreign genes VEGF165 and Ang-1 
into the Ad vector. Three different plasmids - pIRES, pMH5 and pJM17 - were involved 
in this system. pIRES was used because it is a eukaryotic bicistronic expression plasmid 
which carries an internal ribosome entry site (IRES) sequence [from the 
Encephalomyocarditis virus (EMCV)] flanked by two multiple cloning sites (MCS A and 
MCS B) in the expression cassette. Cloning of the VEGF165 and Ang-1 genes into each of 
these MCS will generate the combinatorial 5'-VEGF165+IRES+Ang-1-3' sequence. Such a 
gene arrangement is essential since the IRES sequence sandwiched between these two 
foreign genes allows for the translation of the two genes from the same mRNA transcript. 
In its absence, translation of the downstream cistron of the bicistronic transcript is 
extremely inefficient as only a small proportion of ribosomes recommence scanning after 
completing translation of the upstream cistron and are capable of initiating downstream 
cistron translation (Kozak, 1989; Jackson et al., 1990). Thus, insertion of an IRES 
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element between the two ORFs effectively promotes translation of the downstream 
cistron in a manner which is independent of the 5'-end of the RNA. 
The next is to clone the 5'-VEGF165+IRES+Ang-1-3' sequence directly into an Ad 
vector using the conventional in vitro ligation process. Unfortunately, the large size of the 
Ad genome limits the number of unique, useful restriction sites available for in vitro 
manipulation. Hence, it is easier to first clone the 5'-VEGF165+IRES+Ang1-3' gene 
sequence into the adenoviral shuttle plasmid, pMH5. pMH5 contains Ad type 5 
sequences from bp 22 to 5790 with a deletion of E1 sequences from bp 342 to 3523. At 
the position of deletion, a 1.4 kb fragment of the murine cytomegalovirus (MCMV) 
immediate early gene 1 enhancer/promoter is inserted. The inserted promoter is followed 
by a polycloning oligonucleotide with multiple restriction enzyme sites, as well as the 
simian virus 40 (SV40) polyadenylation signal. Cloning of the 5'-VEGF165+IRES+Ang1-
3' transgene within this polycloning oligonucleotide would thus allow the insert to be 
flanked by MCMV promoter and SV 40 polyadenylation signal as well as Ad E1 
sequences. The resultant shuttle plasmid is co-transfected with pJM17 (a plasmid 
containing almost the entire Ad type 5 genome) into 293 cells, in vivo homologous 
recombination within a sequence common to both plasmids (that is E1 of Ad sequence in 
this case) will target the 5'-VEGF165+IRES+Ang1-3' gene sequence to the desired 
position in the pJM17 vector. The end product is an E1-defective recombinant adenovirus 
that is replication-incompetent, carrying the VEGF165 and Ang-1 genes (Figure 1; 



























Figure 1: Flowchart on 
construction of recombinant 
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1.5.3 Hypothesis 
We hypothesized that the combo therapy approach based on skeletal myoblast 
transplantation together with angiogenic synergy between VEGF165 and Ang-1 would 
provide beneficial effects to the ischemic limb in two ways. Whilst synergistic 
overexpression of VEGF165 and Ang-1 genes would help to restore blood circulation in 
the ishemically damaged muscle fibers through neovasculariztion in a localized and 
targeted fashion, concurrent neomyogeneis from the transplanted skeletal myoblast would 

















2   MATERIALS AND METHODS 
All animals were subjected to humane treatment and all animal procedures were carried 
out in accordance with the Institutional Protocols and Guidelines approved by National 
University of Singapore and the Institutional Animal Care and Use Committee (IACUC) 
Singapore General Hospital. All biopsy and surgical procedures were carried out under 
anesthesia. 
 
2.1 Skeletal myoblasts isolation and culture 
For transplantation of autologous skeletal myoblasts transiently expressing 
VEGF165 and Ang-1 genes to treat hind limb ischemia, skeletal myoblasts were obtained 
from the hind limbs of female adult New Zealand White rabbits (3 to 4.5 kg body weight). 
 
2.1.1 Stimulation of skeletal muscle prior to biopsy 
The site of skeletal muscle biopsy (femoral biceps muscle) was stimulated to 
induce migration of myoblasts to the site of injury/irritation by injecting 0.5 mL mixture 
of ketamine (100 mg/mL) and xylazine (20 mg/mL) at eight points, in and around the 
biopsy site.  
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2.1.2 Biopsy, myoblasts isolation and culture 
Three days after stimulation of the biopsy site, the rabbit was prepared for 
removal of biopsy. The animal was anesthetized by intramuscular injection of ketamine 
(40 mg/kg body weight) and xylazine (8 mg/kg). For alleviation of pain, buprenorphine 
(0.03 mg/kg) and cephalexin antibiotics (15 mg/kg) were administered intramuscularly. 
A skin incision was made on the hind limb, at the previously stimulated site of the 
femoral biceps muscle. Excisional biopsy of the first muscle layer of 1 to 3 g was 
removed and immediately immersed in a serum-free culture medium [Dulbecco's 
Modified Eagle Medium (DMEM) supplemented with 100 units/mL penicillin and 100 
µg/mL streptomycin] on ice. The incision was sutured and the animal was allowed to 
recover. The biopsy specimen was processed immediately under sterile tissue culture 
conditions for the isolation of myoblasts as reported by Qu et al. (2000) with slight 
modifications. 
The muscle biopsy was sterilized in 70 % ethanol for 30 s and rinsed in serum-
free culture medium. The muscle biopsy was minced into a coarse slurry followed by a 
series of enzymatic digestion using 0.2 % collagenase - type XI (C-9407; Sigma) for 90 
min at 37 °C, 2.4 units/mL of dispase (GIBCO-BRL) for 45 min at 37 °C and finally 0.1 
% trypsin-EDTA (Sigma) for 15 min at 37 °C. The muscle cell extract was pre-plated 
three times at 1 h time intervals to get rid of the debris and contaminating population of 
cells to increase the purity of myoblasts isolated from muscle biopsy. Briefly, the cells 
were resuspeneded in a patented Super-medium (Cell Transplants Singapore Pte. Ltd.) 
and plated onto three wells of a six-well tissue culture plate. The cells were allowed to 
settle and adhere to the base of the plate. Non-adherenet cells were transferred to the next 
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three wells of the plate after one hour of plating. The procedure was repeated three times 
before the plates were maintained in a humidified 5 % CO2 atmosphere at 37 °C. Four 
days after seeding, the serum concentration of the culture medium (patented Super-
medium) was increased by feeding the cells with Medium 199 supplemented with 20 % 
fetal bovine serum (FBS), 100 units/mL penicillin, 100 µg/mL streptomycin and 0.1 
mg/mL of gamma-irradiated L-glutamine. The cells were repeatedly passaged to prevent 
pre-mature differentiation and to achieve the required number for subsequent 
transplantation. 
 
2.2 Desmin immunohistochemical staining 
The purity of isolated myoblasts was evaluated by desmin immunohistochemical 
staining using the desmin immunohistology kit as per manufacturers instructions 
(IMMH-5; Sigma). Brifely, skeletal myoblasts were first seeded onto polylysine coated 
sterilized glass slides and cultured to sub-confluence. They were air dried and fixed with 
acetone for 5 min at room temperature. The fixed cells were rehydrated twice in 
phosphate buffered saline (PBS) for 5 min each time. Endogenous peroxidase activity of 
the cells was quenched with 3 % hydrogen peroxide for 5 min at room temperature. The 
slides were washed in PBS for 5 min. Non-specific binding sites were blocked by 
incubating the slides with 1 % BSA for 15 min at 37 °C. Excess blocking solution was 
drained off and the cells were next incubated with biotinylated mouse monoclonal anti-
desmin primary antibody for 2 h at 37 °C. After washing the slides twice with PBS for 5 
min each, ExtrAvidin® - conjugated peroxidase was then added onto the slides and 
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incubated for 20 min at 37 °C. The slides were again washed twice with PBS for 5 min 
each and then dabbed dry. Finally, the peroxidase activity was revealed by applying AEC 
substrate reagent [a mixture of acetate buffer, 3-amino-9-ethylcarbazole (AEC) 
chromogen and 3 % hydrogen peroxide diluted in double distilled water] onto the slides. 
Adequate chromogen development was observed microscopically (Olympus-Japan) up to 
20 min. When sufficient staining has been achieved, slides were rinsed in double distilled 
water and dabbed dry. Aqueous mounting media was applied onto the slides and then 
covered carefully with coverslip. The proportion of desmin positive myoblasts was then 
calculated from the ratio of cells with red stained cytoplasm and those unstained ones, 
obtained from counts of various microscopic fields.  
 
2.3 Myoblasts labeling for cell fate monitoring  
2.3.1 nlsLacZ reporter gene labeling 
Isolated skeletal myoblasts were transduced with nlsLacZ reporter gene (LacZ 
reporter gene with nuclear localization signal) to allow monitoring of cell fate after 
transplantation. 
 
2.3.1.1 Retroviral vector propagation and purification 
Moloney Murine Leukemia Virus (MMLV) engineered to carry the bacterial 
nlsLacZ gene, which encodes the bacterial enzyme β-galactosidase, was kindly gifted by 
A/P Reida Meshanwe El-Oakley. The virus was replication defective [by deletion of 
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sequences coding for essential proteins required for the packaging of the viral particles 
(Miller and Rosman, 1989; Vile et al., 1996)] and was packaged in FLY-A4 cells derived 
from human fibrosarcoma HT-1080 cells (American Type Culture Collection). FLY-A4 
cells were cultured to confluence for 3 to 4 d in DMEM supplemented with 10 % FBS in 
a humidified, 5 % CO2 atmosphere at 37 °C. The supernatant was then collected and 
filtered through a 0.2 µm filter. 
 
2.3.1.2 nlsLacZ reporter gene retroviral transduction into myoblasts 
nlsLacZ reporter gene was retrovirally transduced into the skeletal myoblasts by 
incubating the cells with neat concentration of the filtered supernatant from FLY-A4 cells 
for 24 h in a humidified, 5 % CO2 atmosphere at 37 °C. The transduction procedure was 
repeated twice consecutively for 2 d to achieve optimum transduction efficiency. 
 
2.3.1.3 Histochemistry for β-galactosidase expression 
To detect β-galactosidase expression, skeletal myoblasts transduced with nlsLacZ 
were washed twice with PBS and fixed with 0.5 % glutareldehyde for 15 min at room 
temperature. After twice rinsing with PBS for 5 min each, the cells were incubated 
overnight at 37 °C with 40 mg/mL 5-bromo-4-chloro-3indoyl-β-D-galactopyranosid (X-
gal; Bio-Rad), 30 mM potassium ferricyanide, 30 mM potassium ferrocyanide and 2 mM 
magnesium chloride in PBS. At the end of the incubation period, the cells were rinsed in 
PBS and then observed under light microscope (Olympus-Japan) for bluish green stained 
nuclei. 
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2.3.2 BrdU labeling 
Since nlsLacZ retroviral transduction efficiency was less than 100 %, half of the 
isolated skeletal myoblasts were also double labeled with the thymidine analogue 5-
bromo-2-deoxy-uridine (BrdU) using the BrdU Labeling and Detection Kit II (Roche 
Molecular Biochemicals). 
 
2.3.2.1 BrdU incorporation into myoblasts 
BrdU was incorporated into skeletal myoblasts by incubating the cells with the 
BrdU labeling reagent (1:500 dilution with culture medium) for 48 h in a humidified, 5 % 
CO2 atmosphere at 37 °C.  
 
2.3.2.2 Immunohistochemical staining for BrdU  
To ascertain for successful BrdU incorporation, skeletal myoblasts were grown on 
polylysine coated sterilized glass slides. The slides were air dried and fixed with absolute 
ethanol for 20 min at -20 °C. The cells were rehydrated twice in PBS for 5 min each. 
Following this, endogenous peroxidase activity was quenched from the tissues with 
methanolic hydrogen peroxide (1 part 3 % hydrogen peroxide to 4 parts of methanol) for 
20 min at room temperature. The slides were washed twice in PBS for 5 min each and 
then dabbed dry. Non-specific binding was next blocked with Ultra-V blocking agent 
(LabVision) for 7 min at room temperature. Excess blocking solution was drained off and 
the cells were next incubated with mouse anti-BrdU primary antibody (1:100 dilution; 
Roche Molecular Biochemicals) for 30 min at 37 °C. At the end of the incubation period, 
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the slides were washed four times with PBS for 5 min each and then dabbed dry. Rabbit 
anti-mouse IgG-HRP conjugated secondary antibody (1:500 dilution; Chemicon) was 
then added onto the slides and incubated for 2 h at room temperature. The slides were 
again washed four times with PBS for 5 min each. Finally, the peroxidase activity was 
revealed by applying DAB (3,3-diaminobenzidine) substrate reagent (LabVision) onto 
the slides. Adequate chromogen development was observed microscopically (Olympus- 
Japan) for 5 to 15 min. When sufficient staining has been achieved, slides were rinsed in 
double distilled water and dabbed dry. They were observed under light microscope for 
brown stained nuclei. 
 
2.3.3 DAPI labeling 
The other half of BrdU unlabeled cells were also double labeled with 4,6-
diamidino-2-phenylindole (DAPI) to cover any unlabeled cells from the previous nlsLacZ 
transduction procedures. This fluorescent dye binds to the double stranded DNA. 
 
2.3.3.1 DAPI incorporation into skeletal myoblasts 
The cells were trypsinized as per normal and the cell pellet was resuspended in 1 
X DAPI [diluted from a 10 X stock solution (0.2 mg/mL DAPI; Sigma) with 0.9 % 
sodium chloride] for 40 min in a dark and humidified, 5 % CO2 atmosphere at 37 °C.  
Successful incorporation of DAPI into the cells was ascertained by observing the 
labeled cells under fluorescent microscope (Olympus-Japan) for blue fluorescent nuclei. 
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2.4 Adenoviral transduction of VEGF and Ang-1 genes into skeletal 
myoblasts  
Isolated skeletal myoblasts were transduced with bicistronic Ad-vector carrying 
both hVEGF165 and hAng-1 genes (Ad-Bicis), only hVEGF165 gene (Ad-VEGF165) or 
without angiogenic genes (Ad-Null). These viruses were kindly provided by Dr Ge 
Ruowen, Laboratory of Molecular Angiogenesis, National University of Singapore. 
 
2.4.1 Adenoviral vector propagation and purification 
Human adenovirus type-5 was used in this study. The virus was deficient for the 
early region 1 (E1) which was essential for its replication. As such, it was replication 
defective in all cells except in the E1-complementing 293 cells, a cell line derived from 
human embryonic kidney cells transformed by sheared Ad type 5 DNA.  
Approximately three million 293 cells were seeded in a tissue culture treated 
flasks that have a growth surface area of 75 cm square (T-75) and this was allowed to 
grow for 4 d to reach confluence containing about 24 million cells. These cells were 
grown in DMEM supplemented with 10 % FBS and cultured in a humidified, 5 % CO2 
atmosphere at 37 °C.  
At the end of the 4 d, Ad was propagated by infecting the confluent 293 cells. The 
thawed, cryopreserved virus was dispensed into the 293 monolayer that was covered with 
20 mL of culture medium and this was then incubated for another 4 d in the humidified, 5 
% CO2 atmosphere at 37 °C till complete cytopathic effect was observed. Essentially, this 
is characterized by the change in the morphology of the cells from an attached, polygonal 
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appearance to a rounded, grape-like, detached one. The supernatant was then collected 
and filtered through a 0.2 µm filter. Ten milliliters of the filtered supernatant was mixed 
with 20 mL of culture medium and this was dispensed into a fresh T-75 that has already 
been seeded with 24 million 293 cells. Again, this was maintained for 4 d until complete 
cytopathic effect was observed. At the end of which the supernatant was collected and the 
above procedure of transferring the virus to a fresh 293 monolayer was repeated for 
subsequent maintenance of the Ad. 
 
2.4.2 Adenoviral transduction of skeletal myoblasts 
Primary myoblasts already expressing nlsLacZ gene from a retroviral promoter 
and BrdU/DAPI labels, were transduced with either Ad-Bicis, Ad-VEGF or Ad-Null by 
incubating the cells with neat concentration of the filtered supernatant from 293 cells pre-
infected with the respective Ad. This was maintained for 24 h in a humidified, 5 % CO2 
atmosphere at 37 °C. To achieve optimum transduction efficiency, this transduction 
procedure was repeated for a total of three times by replacing the used virus medium with 
fresh ones from the filtered supernatant of 293 cells (pre-infected with the respective Ad) 





2.4.3 Immunohistochemical staining for VEGF and Ang-1 expression 
VEGF and Ang-1 genes overexpression from the transduced skeletal myoblasts 
was verified by either fluorescent or non-fluorescent immunostaining. 
 
2.4.3.1 Double fluorescent immunostaining for VEGF and Ang-1 expression 
In vitro Ang-1 and/or VEGF expression from Ad-Bicis and Ad-VEGF transduced 
myoblasts was detected with fluorescent immunostaining. Ad-Bicis or Ad-VEGF 
transduced skeletal myoblasts were grown on polylysine coated sterilized glass slides and 
cultured to subconfluence for about 2 to 5 d. They were then immunostained as described 
earlier in section 2.3.2.2 using rabbit anti-mouse Ang-1 (1:30 dilution; Chemicon) and/or 
mouse anti-human VEGF (1:50 dilution; PharMingen) primary antibodies. The reaction 
between the Ang-1 primary antibody and its antigen was visualized by using goat anti-
rabbit IgG TRITC conjugated secondary antibody (1:100 dilution; Sigma) while those of 
VEGF was visualized by using goat anti-mouse IgG FITC conjugated secondary antibody 
(1:100 dilution; Sigma). The red (Ang-1) or green (VEGF) fluorescent signals emitted 
was then observed under a fluorescent microscope (Olympus-Japan). The cell nuclei were 
counterstained with mounting media containing DAPI (Vector shield).  
The transduction efficiency of Ad-Bicis was obtained by calculating the 
proportion of VEGF positive myoblasts from the ratio of cells with green fluorescence to 
total number of cells, obtained from counts of 10 microscopic fields (Olympus-Japan). 
Similarly, the proportion of Ang-1 positive skeletal myoblasts was then calculated from 
the ratio of cells with red fluorescence to total number of cells, obtained from counts of 
various microscopic fields. 
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2.4.3.2 Non-fluorescent immunostaining for VEGF expression 
In vitro VEGF expression from Ad-Bicis and Ad-VEGF transduced myoblasts 
was confirmed with non-fluorescent immunostaining. This was performed as described 
earlier in section 2.3.2.2 using mouse anti-human VEGF (1:50 dilution; PharMingen) 
primary antibody. The reaction between the VEGF primary antibody and its antigen was 
visualized by using biotinylated goat anti-polyvalent secondary antibody (LabVision) 
followed by streptavidin peroxidase (LabVision). The cells were sometimes 
counterstained with hematoxylin to visualize the nuclei.  
The proportion of VEGF165 positive myoblasts was then calculated from the ratio 
of cells with brown stained cytoplasm to total number of cells, obtained from counts of 
various microscopic fields.  
 
2.4.4 Measurement of VEGF secretion  
The pattern of transient VEGF gene expression was assessed by measuring the 
level of VEGF secreted into the culture medium using enzyme linked immunosorbent 
assay (ELISA). The culture medium containing the secreted VEGF protein, termed as 
conditioned medium, was collected every 48 h beginning from the last Ad transduction 
over a time period of 28 days. ELISA for VEGF165 was performed using ChemiKineTM 
Human VEGF Sandwich ELISA kit (Chemicon International, Inc.) as per suppliers 
instructions. Briefly, 100µl of each of the standards (5000 pg/mL, 1000 pg/mL, 200 
pg/mL, 40 pg/mL and 0 pg/mL of VEGF standards) as well as the conditioned media 
obtained at different time points were dispensed into their respective wells pre-coated 
with mouse monoclonal antibodies generated against human VEGF165. Each of the 
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conditioned media samples was pre-diluted with PBS prior to their addition into the 
wells. Twenty-five microliters of diluted biotinylated rabbit anti-human VEGF polyclonal 
antibody was then added into each well. The plate was sealed well to prevent evaporation 
and then incubated at room temperature for 3 h. Following this, each well was washed 
with 250 µL of wash buffer for a total of five times. Fifty microliters of diluted 
streptavidin-alkaline phosphatase was next dispensed into each well and incubated at 
room temperature for 45 min. The wells were again washed five times. Two hundred 
microlitres of colour reagent solution was dispensed into each well and the colour was 
allowed to develop at room temperature until the VEGF standard of concentration 5000 
pg/mL reached an optical density (OD) reading of 1.6 to 1.8 OD units. The OD of each 
well was determined by using a microplate reader set to 490 nm wavelength with high 
shaking mode. Once this was achieved, 50 µL of stop solution was added to each well to 
stop the reaction. A final reading was then taken. The OD readings of the samples were 
compared to the log-log graph standard curve (Figure 2) generated from the VEGF 






























Figure 2. VEGF log-log standard curve 
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2.5 Hind limb ischemia model  
2.5.1 Animal groupings 
The animals were randomized into five groups to receive intramuscularly injected 
(i) DMEM group-1 (n=8), (ii) non-transduced myoblast transplanted group-2 (n=10), (iii) 
myoblasts transduced with Ad-Null group-3 (n=10), (iv) myoblasts transduced with Ad 
carrying VEGF165 gene group-4 (n=10) and (v) myoblasts transduced with Ad carrying 
bicistronic VEGF and Ang-1 genes group-5 (n=10). 
 
2.5.2 Development of animal model for hind limb ischemia  
The animals were anesthetized with an intramuscular injection of ketamine (40 
mg/kg) and xylazine (8 mg/kg). Supplementary administration of the analgesic 
buprenorphine (0.03 mg/kg) and cephalexin antibiotics (15 mg/kg) were injected 
intramuscularly. 
Femoral artery of the left hind limb was exposed and freed through a longitudinal 
incision from the inguinal ligament to a point just proximal to the patella. Multiple 
ligatures of the artery and all of its branches, beginning from the inguinal ligament right 
down to the point where it just bifurcates into the popliteal and saphenous arteries, were 















2.5.3 Confirmation on ischemic condition of animal model by angiography 
As described earlier, the right femoral artery was then exposed and freed through 
a longitudinal skin incision. A 22 G intravenous catheter was inserted to infuse 2000 
units of heparin followed by 10 mL of the iodinated contrast medium (Iomeprol, 
IOMERON® 350, Bracco). Serial filming of the left hind limb was done using Advantex 
angiography machine (General Electric, USA). Following this, the catheter was removed 
and the punctured artery was closed by ligation. Wounds were then closed.  
 
2.6 Myoblast transplantation 
In order to mimic the clinical setting more closely, inflammatory response after 
induction of hind limb ischemia was allowed to heal for approximately 10 d before 




















Figure 3. Rabbit hind limb ischemia model. Blue crosses show sites of ligations. 
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A total of six to eight T-75 flasks confluent with skeletal myoblasts were 
trypsinized. They were labeled with nlsLacZ and BrdU/DAPI and genetically modified 
with Ad-Null (group-3), Ad-VEGF (for group-4) or Ad-Bicis (for group-5) transduction. 
The old medium was first aspirated from the flask and the adhering cell monolayer was 
washed once with a sufficient volume of Hanks Balanced Salt Solution. Trypsin/EDTA 
solution (1X) was then added to cover the adhering cell layer to allow for detachment of 
cells from the growth surface of the flask. The culture flask was checked for complete 
removal of the cells and cell suspension was centrifuged at 1500 rpm, 18 °C for 5 min in 
a refrigerated centrifuge. The supernatant was discarded while the cell pellet was washed 
twice with Hanks Balanced Salt Solution before resuspending them in a total volume of 
3 mL basal DMEM. The suspension was kept on ice for immediate transplantation. 
The animals were anesthetized as earlier described and the tensor muscle of fascia 
lata, which was in close proximity with and along the projection of the femoral ligation 
site, was exposed through a longitudinal skin incision. Polypropylene sutures (Prolene 4-
0 metric) were placed approximately 0.5 cm into the exposed muscle at four sites to 
permanently mark a rectangular site for injection. The cell suspension was then 
transplanted within this marked region through multiple injections of 100 µL volume 
each with the use of a 1-mL syringe and a 27-gauge needle. For each injection, the tip of 
the needle was inserted into the muscle at an angle of about 45° to its maximum 
allowable depth. The cell suspension was then slowly injected. For subsequent injections, 
the needle was withdrawn slowly and reinserted. For DMEM group, multiple injections 
of a total volume of 3 mL basal DMEM was injected instead of the cell suspension. After 
the final injection, the skin was sutured. This procedure of injecting myoblasts into an 
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exposed muscle gave much more reproducible results than did injecting the cells through 
the skin. 
 
2.7 Post transplantation animal care 
To avoid host immune rejection of the transplanted cells, animals in all the cell 
transplanted groups were immunosuppressed with 5mg/kg of cyclosporine on a daily 
basis 2 to 3 d before transplantation and thereafter two weeks after transplantation. The 
animals in all groups were also injected with the antibiotics cephalexin for up to 5 d after 
transplantation to counter any possible infection. 
 
2.8 Angiography 
Approximately eight weeks after transplantation, augmentation of collateral vessels 
in the ischemic limb was assessed by angiography. 
The procedure followed that mentioned in section 2.5.3. Vascularization of the left 
thigh was quantified by direct counting of the number of arteries crossing 15 lines, drawn 
vertically across the midthigh [as reported by Pu et al. (1993) with slight modifications]. 
Vessel numbers from different animals within each group were summed up and averaged 
to obtain the angiographic score for that group. Collateral patterns were also observed.  
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2.9 Animal euthanasia 
Animals were euthanized with an overdose injection of sodium pentobarbital 
through the marginal vein of the ear. Immediately after the sacrifice, the left hind limb 
was dissected and the region of transplantation, previously marked by the four sutures on 
the tensor muscle of fascia lata, was removed for histological studies. 
 
2.10 Histological studies 
Harvested tissues were dissected into small segments and each one was covered 
with O.C.T. compound before being snap frozen in partially thawed isopentane, 
previously cooled to 165 °C in liquid nitrogen. Multiple cryosections of 8 to 12 µm 
thickness were cut on a cryostat and placed on glass slides for histological studies. 
 
2.10.1 Identification of transplanted skeletal myoblasts 
Viability and identification of the transplanted donor skeletal myoblasts six to 
eight weeks after transplantation was established with X-gal staining for nlsLacZ 
expression (12 µm thickness), BrdU staining (8 µm thickness) and DAPI fluorescence 
microscopic observation (12 µm thickness) on the muscle tissue sections. These were 
performed as mentioned in sections 2.3.1.3 (for nlsLacZ), 2.3.2.2 (for BrdU) and 2.3.3.1 
(for DAPI). For nlsLacZ staining, sections were occasionally counterstained with 
hematoxylin to ascertain the position of nucleus in the tissue. 
Whilst LacZ expression is well understood to be retained in cells even after 
multiple divisions for a long period of time (due to the gene being incorporated into the 
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host cell genome), BrdU and DAPI labels have been obseserved to be retained for up to 
six and eight weeks respectively. It must be noted, however, that DAPI fluorescence was 
emitted at a much weaker signal at eight weeks post-labeling compared to its earlier 
counterpart. 
 
2.10.2 Capillary density and vessel maturation index quantification 
To measure capillary density and vessel maturation index, the tissue sections (10 
µm thickness) were stained for von Willebrand Factor VIII (vWF) and smooth muscle 
actin (SMA) to detect capillary endothelial cells and smooth muscle layer, respectively. 
The tissue sections were immunostained as described earlier in section 2.4.3.1 
using sheep anti-human vWF-FITC conjugated primary antibody (1:50 dilution; Acris) 
and mouse anti-α SMA primary antibody (1:100 dilution; Sigma). The reaction between 
the SMA primary antibody and its antigen was visualized by using rabbit anti-mouse-
rhodamine conjugated secondary antibody (1:100 dilution; Chemicon) and observed 
under a fluorescent microscope (Olympus-Japan) for green (vWF) or red fluorescence 
(SMA). 
For each tissue section, the number of capillaries was counted from four randomly 
selected microscopic fields under a 200x objective. A total of four different tissue 
sections from each animal, with two animals randomly selected per group, were used for 
measuring the final average capillary density. Vessel maturation index was calculated as 
the number of SMA-stained vessels over the total number of vessels within the field of 
view (obtained from the merged vWF and SMA stained vessel picture), counted under a 
200x objective microscopic field. 
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2.10.3 Smooth muscle actin counterstaining on LacZ/DAPI positive sections 
To observe for possible correlation between the transplanted region and any 
increase in blood vessel density, sections that were positive for extensive LacZ 
expression/DAPI fluorescence were also counterstained with SMA. For this, X-gal 
staining was first carried out as mentioned in section 2.3.1.3 or DAPI fluorescence was 
observed under fluorescent microscope, followed by SMA staining. This was performed 
as described earlier in section 2.3.2.2 using mouse anti-α SMA primary antibody (1:100 
dilution; Sigma) primary antibody. The reaction between the α SMA primary antibody 
and its antigen was visualized using rabbit anti-mouse IgG-HRP conjugated secondary 
antibody (1:500 dilution; Chemicon) for non-fluorescent staining, or rabbit anti-mouse 
IgG-rhodamine conjugated secondary antibody (1:100 dilution; Chemicon) for 
fluorescent staining. For the latter, the slides were observed for red fluorescence under 
the microscope (Olympus-Japan). 
 
2.10.4 T-lymphocytes immunohistochemical staining 
Serial LacZ positive tissue sections were used for immunohistochemical staining 
to visualize T-lymphocyte infiltration at the site of the graft. Immunohistochemical 
staining was carried out using the protocol as detailed earlier in section 2.3.2.2 using 
mouse anti-rabbit T-lymphocyte-FITC conjugated primary antibody (1:50 dilution; 
Serotec). The reaction between the T-lymphocyte primary antibody and its antigen was 
visualized by using rabbit anti-mouse IgG-HRP conjugated secondary antibody (1:250 
dilution; Chemicon) and revealed by DAB substrate. It was observed under a light 
microscope (Olympus-Japan) for brown stained cellular membrane. 
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2.10.5 Myosin heavy chain immunohistochemical staining 
To observe for signs of possible neomyogenesis in the transplanted area, tissue 
sections that were positive for X-gal stain/DAPI fluorescence were counterstained for the 
skeletal muscle specific marker myosin heavy chain. 
Immunohistochemical staining was carried out using the protocol as detailed 
earlier in section 2.3.2.2 using mouse anti-rabbit skeletal muscle myosin heavy chain 
primary antibody (1:100 dilution for non-fluorescent staining or 1:500 dilution for 
fluorescent staining; Sigma). The reaction between the myosin heavy chain primary 
antibody and its antigen was visualized by using rabbit anti-mouse IgG-HRP conjugated 
secondary antibody (1:500 dilution; Chemicon) and revealed by DAB substrate. For 
fluorescent staining, rabbit anti-mouse IgG-rhodamine conjugated secondary antibody 
(1:1000 dilution; Chemicon) was added and observed under a fluorescent microscope 
(Olympus-Japan) for red fluorescence. 
 
2.10.6 VEGF immunohistochemical staining on LacZ positive sections 
Tissue sections that were positive for X-gal stain were counterstained for VEGF 
to detect in vivo expression of this angiogenic growth factor. Staining procedure followed 
that as mentioned in section 2.4.3.2. 
 
2.11 Statistical analysis 
 Using SPSS version 10.0 (SPSS Inc.), one-way ANOVA was used to determine if 
there exist any significant differences among the means of the different groups. Once this 
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was established, post-hoc pairwise multiple comparisons using the LSD (least significant 
difference) option were used to determine which are the means that differed. Normalcy of 
the data was tested using the Chi-square and one-sample Komolgorov-Smirnov tests.  
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3   RESULTS 
 
3.1 Skeletal myoblasts isolation and culture 
Besides skeletal myoblasts, the freshly isolated cells from rabbit hind limb skeletal 
muscle biopsy samples also contained a mixture of muscle-derived cells, including 
fibroblasts and adipocytes. Skeletal myoblasts were indicated by their typical 
cytoskeleton with larger spherical shape and having jagged edges (Figure 4, arrowheads). 
Blood cells and residual undigested muscle tissue were also present in culture. At day 
one, most of the cells were attached to the flask base, most of which acquired the spindle-
shaped configuration typical of myoblasts while others retained their spherical shape with 
jagged edges. By day four, the cells started to form colonies. If left unpassaged, skeletal 
myoblasts multiplied until they reached confluence by day seven where they attained a 
particular wave-like alignment that radiates from a common origin. Thereafter, myogenic 
cells, which ceased dividing, commenced the in vitro fusion process when allowed to 
proliferate to over-confluence in low serum concentration, which resulted in formation of 
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Confluent Myotube 
Figure 4. Phase contrast photomicrographs on morphology of rabbit primary 
myoblasts culture. Top and middle rows: Early culture of cells at 0h (400x 
magnification), 1d, 4d and 7d post-isolation (300x magnifications). Black arrowheads
point to suspected myoblasts isolated. Bottom row: Late culture of cells at confluence
phase (60x magnification) and an enlarged picture showing myotube formation, with
white arrows indicating presence of multiple nuclei. 
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3.2 In vitro characterization of skeletal myoblasts 
The population of muscle-derived cells after three times preplating and initial 
culture in the patented Supermedium displayed > 75-80 % positive desmin expressing 
cells (Figure 5). Primary skeletal myoblasts were transduced with the retroviral nlsLacZ 
reporter gene and labeled with BrdU and DAPI to allow monitoring the fate of skeletal 
myoblasts after transplantation at various time points. In vitro retroviral transduction 
efficiency of skeletal myoblasts for nlsLacZ reporter gene was more than 80 % as 
assessed by X-gal staining for β-galactosidase activity (Figure 6). BrdU and DAPI were 
also efficiently incorporated into the cells (Figure 6).  
Skeletal myoblasts labeled with the three markers were also transduced with Ad-
Bicis, only Ad-VEGF or Ad-Null vectors. Dual fluorescent immunostaining of skeletal 
myoblasts for VEGF165 and Ang-1 after transduction with the Ad-Bicis revealed that 
more than 75-80 % of the cells simultaneously expressed both the growth factors (Figure 
7). VEGF165 expression was confirmed with non-fluorescent staining, revealed by DAB 
substrate (Figure 8). Cells transduced with the Ad-VEGF165 also expressed the growth 
factor as revealed by fluorescent immunostaining for VEGF165 (Figure 9). This was again 
confirmed with non-fluorescent immunostaining, revealed by DAB substrate (Figure 9). 
The secretion level of VEGF165 in vitro from the Ad-VEGF165 transduced skeletal 
myoblasts was assessed by ELISA. VEGF165 secreted into the culture medium was 
collected at a regular interval of 2 d, extending for a total period of 28 d of observation. 
The secretion level of hVEGF165 from the Ad-Bicis transduced skeletal myoblasts peaked 
at 6 days post transduction (35.04±1.91 ng/mL) while that of Ad- VEGF165 transduced 
















































Figure 5. Desmin immunohistochemical staining to assess purity of myoblasts
population isolated. Top: Rabbit primary myoblast population were > 75-80 % pure for 
desmin expression, revealed by AEC substrate (300x magnification). Bottom: Positive
control using human myoblast cell line (Cell Transplants Singapore Pte. Ltd.), lightly





















































Figure 6. Nuclear labeling of rabbit myoblasts to allow monitoring of cell fate after
transplantation. Top: In vitro retroviral transduction efficiency of myoblasts with
nlsLacZ reporter gene was about 80 %, as detected by X-gal staining (400x 
magnification). Middle: BrdU incorporated myoblasts detected by
immunohistochemical staining (300x magnification). Bottom: DAPI labeled myoblasts
















































Figure 7. Dual immunofluorescent staining of Ad-Bicis transduced myoblasts to 
detect VEGF165 and Ang-1 expression. More than 75-80 % of the cells simultaneously 
expressed both growth factors. Top: FITC fluorescence of VEGF165 expressing 
myoblasts overlayed with DAPI fluorescence. Middle: Corresponding TRITC
fluorescence of Ang-1 overlayed with DAPI fluorescence. Bottom: Merged





















































Figure 8. VEGF165 immunohistochemical staining of Ad-Bicis transduced 
myoblasts. Top: VEGF165 expression from Ad-Bicis transduced myoblasts was 
confirmed with non-fluorescent staining, revealed by DAB substrate, and hematoxylin
counterstaining. Bottom: Negative control with primary antibody omitted, and



















































Figure 9. VEGF165 immunohistochemical staining of Ad-VEGF transduced 
myoblasts. Top: FITC fluorescence of VEGF165 expressing myoblasts overlayed with 
DAPI fluorescence. Bottom: VEGF165 expression confirmed with non-fluorescent 

















































Figure 10. Measurement of VEGF165 secretion from Ad transduced myoblasts by 
ELISA.  Top: Level of VEGF165 secreted from Ad-Bicis transduced myoblasts peaked 
at 6 days post transduction (35.04±1.91 ng/mL). Bottom: Level of VEGF165 secreted 


























































3.3 Fate of transplanted skeletal myoblasts 
Following transplantation into rabbit ischemic skeletal muscles, extensive survival 
of skeletal myoblasts was observed at the site of the graft (Figure 11-14). A proportion of 
nlsLacZ positive donor skeletal myoblasts successfully integrated into mature or 
regenerating host muscle fibers to form heterokaryons. The donor skeletal myoblast 
nuclei continued to express nlsLacZ reporter gene as observed by histochemical staining 
for β-galactosidase activity. Fusion to form mature host fibers was evident from the 
strictly peripherally located green donor nuclei that were interspersed and aligned with 
the host purple nuclei as visualized by counterstaining with hematoxylin. This was 
further confirmed by immunostaining for BrdU and observing for DAPI fluorescence 
(Figure 11). On the other hand, fusion to regenerating host muscle fibers was indicated by 
presence of some centrally located nlsLacZ donor nuclei (Figure 12). The other fates of 
the transplanted myoblasts include fusion to other implanted myoblasts (Figure 13), 
remained quiescent as mononucleated cells (Figure 14) or death. One possible cause of 
death of these transplanted myoblasts is host immune rejection as revealed by presence of 



























































Figure 11. Fate of transplanted skeletal myoblasts - fusion to mature host fibers.
Top row: nlsLacZ expressing donor myoblasts (green nuclei) in the host tissue of group-
3 at 6 w after transplantation as revealed by X-gal staining, and counterstained with 
hematoxylin to visualise host nuclei (purple). Tissue section from DMEM injected 
group at 8 w post-treatment was used as negative control, also counterstained with
hematoxylin. (600x magnifications) Middle row: Immunohistochemical staining on 
tissue section from group-4 at 6 w after transplantation for BrdU positive donor 
myoblasts, revealed by DAB substrate (300x magnification). Negative control with 
primary antibody omitted (150x magnification). Arrows indicate representative
















































Figure 12. Fate of transplanted skeletal myoblasts  fusion to regenerating host 
fibers. LacZ expressing donor myoblasts (green nuclei) at site of grafting in group-2 at 
6 w after transplantation as revealed by X-gal staining (200x magnification). A 
proportion of these green donor nuclei were centrally located in the muscle fiber,
suggesting their fusion to regenerating fibers. Arrows indicate representative centrally
located donor nuclei. 
Figure 11 continued. Fate of transplanted skeletal myoblasts  more evidence of 
fusion to mature host fibers. DAPI labeled donor myoblasts observed under
fluorescence microscopy, in group-5 at 8 w  after transplantation confirmed fusion to
host fibers (150x magnification). Absence of DAPI fluorescence in tissue section from 
DMEM injected group at 8 w post-treatment used as negative control (100x 
magnification). Arrows indicate representative transplanted cells. 
















































Figure 13. Fate of transplanted skeletal myoblasts  fusion to other implanted 
myoblasts. LacZ expressing donor myoblasts (green nuclei) in an ischemic region of
the limb in group-4 animal, as revealed by X-gal staining at 6 w after transplantation 
(100x magnification). The mass of β-galactosidase expression at certain sites (indicated 
by red arrows) possibly involved fusion amongst implanted myoblasts. White arrows 

















































Figure 14. Fate of transplanted skeletal myoblasts  remained quiescent as 
mononucleated cells. Top: LacZ expressing donor myoblasts (green nuclei) remained
quiescent as mononucleated cells in-between degenerating muscle fibers of an ischemic
area of a group-2 animal, as revealed by X-gal staining at 6 w after transplantation 
(100x magnification). Bottom: Confirmation by presence of haphazardly arranged DAPI
labeled cells in another ischemic region of a group-4 animal at 6 w after transplantation 


















































Figure 15. T-lymphocyte immunohistochemical staining to detect immune 
rejection of transplanted skeletal myoblasts. Site of cell grafting (not shown) at an 
ischemic region of a group-4 animal at 6 w after transplantation revealed presence of
infiltrating T-lymphocytes, suggesting death of transplanted myoblasts by host immune 
rejection. Section was counterstained with eosin to visualize muscle fiber architecture
(200x magnification). Arrows indicate representative T-lymphocytes revealed with 
DAB substrate. 
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3.4 Animal model preparation and angiographic assessment 
Partial ischemia was induced in left hind limb of the rabbits by surgical ligation of 
the external iliac artery and superficial femoral artery, leaving the internal iliac artery 
intact. Eight-point permanent ligation of the external iliac and femoral arteries was 
carried out to achieve complete occlusion of the blood flow to produce sufficient 
ischemia (Figure 16). In addition, contrary to most previously documented studies that 
excised a substantial part of the femoral artery, we modified the procedure of animal 
model development by occluding a short sequence of this vessel that was sufficiently 
long to avoid simple jumping of collaterals across the ligature in order to make it 
clinically more relevant and with similarity to the natural obliterative disease process. 
Similar to studies that developed animal models of hind limb ischemia by excision of the 
femoral artery, our animal model demonstrated complete occlusion of the ligated blood 
vessel and its tributaries, as revealed by angiographic assessment at 10 d post ligation. 
Several radiographically visible corkscrew collaterals arising from the internal iliac artery 
were also observed in the limb at this time point (Figure 16A-E), and this appears to be 
more than in the nonoccluded hind limbs (Figure 16). Despite such collateral growth in 
the thigh, perfusion in the lower leg does not reach maximal normal values (Schaper et 
al., 1976), thus leaving substantial room for therapy. We also witnessed occasional 
gangrene and gross impairment of function (shown most obviously by limping and the 
appearance of skin necrosis, and necrotic black toes) within a short period after the 
ligation procedure, thus confirming the success of the model development. 
At 6 w after treatment, significantly increased angiographic collateral blood vessels 
count was observed in group-5 (25.14±5.14) as compared to group-2 (4.67±3.49; P=.024) 
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or DMEM-injected group-1 (3.18±7.76; P=.022) (Figure 17F-K). These collateral blood 
vessels represented a network of newly formed arteries as they were not detected before 
treatment. They were distributed in a broad area of the ischemic muscles sprouting from 
the internal iliac artery towards the distal medial thigh region. However, angiographic 
score from the Ad-VEGF myoblast transplantation in group-4 (13.62±4.52; P=.181) or 
Ad-Null myoblast taransplantation in group-3 (6.09±0.09; P=.057) were not significantly 
different from the scores of group-5, though group-5 still sustained the highest value 
amongst all groups (Figure 17K). In addition, several newly formed collateral vessels 
were also detectable in the DMEM injected control group-1 (Figure 17J). This is similar 
to a previous report by Cao et al. (2003) who stated that such a compensatory effect of 
ischemia-induced collateral growth was normally observed in models 6 to 8 w after 
ligation. 
There were no animal deaths related to the skeletal myoblast transplantation 
procedure. On the whole, all animals completed the entire study duration successfully, 










































































Figure 16. Creating rabbit model of left hind limb ischemia. Left: Schematic 
diagram showing sites of multiple ligations (blue crosses) of left femoral artery,
beginning from inguinal ligament right down to where it bifurcates into the popliteal
and saphenous arteries. Right: Angiogram on normal rabbit hind limb before ligation. 


















































to detect collateral 
formation.  
Left column (A-E): 
Baseline angiograms at  
10 days post-ligation and 
before treatment.  
Right column (F-J): 
Angiograms of the same 
corresponding rabbits 6 w 
after intramuscular 
injection of either Ad-Bicis 
transduced myoblasts,  
Ad-VEGF transduced 
myoblasts, Ad-Null 
transduced myoblasts,  
non-transduced myoblasts 
or only DMEM.  
White asterisks mark 
ligation sites. Red arrows 



































































































Figure 17K. Angiographic score from quantification of collaterals in different 
treatment groups. Angiographic blood vessel count revealed enhanced
neovascularization in Ad-Bicis transduced myoblasts treated group.  P=.022 vs DMEM; 
P=.024 vs Myoblast; P=.057 vs Ad-Null Myo; P=.181 vs Ad-VEGF Myo. 
 
*DMEM group-1 (n=4), Myoblast group-2 (n=4), Ad-Null Myo group-3 (n=2), Ad-





























3.5 Blood vessel density assessment 
As the angiographic analysis detects only relatively larger size collateral vessels and 
not the finer capillary network, a double immunolocalization using fluorescent vWF and 
SMA antibodies was performed. It revealed much superior capillary density [number of 
vWF-stained capillaries/high power microscopic field (200x)] in group-5 (19.04±1.59) as 
compared to group-4 (15.31±1.55; P=.009), group-3 (6.53±0.97; P=.000), group-2 
(5.69±0.51; P=.000) and group-1  (3.03±0.20; P=.000) (Figure 18A-P). 
A large proportion of blood vessels in group-5 possessed a thick smooth muscle cell 
coating as revealed by the merged images of vWF and SMA, thus suggesting the 
maturation of these newly formed vessels (Figure 18E, J, O). This was further confirmed 
using non-fluorescent DAB chromogenic immunohistochemical staining for SMA 
(Figure 19A-B). It revealed a more detailed observation of numerous fine, small vessels 
surrounding the periphery of muscle fibers, albeit at a weaker stain. However, such high 
density of mature vessels were also observed in the other treatment groups as calculated 
by their similar maturation index [number of SMA-stained vessels / total number of 
vessels obtained from the merged vWF and SMA images, counted under a high power 
microscopic field (200x)] (Figure 18Q). We did not observe formation of hemangiomas 
in any of the treatment groups. In addition, DAPI or LacZ expressing donor skeletal 
myoblasts and SMA positive vessels showed a proportional degree of expression, be it in 
ischemic (Figure 20-21) or viable muscle area (Figure 22). At the site of extensive 
DAPI/Lac-Z expression, a corresponding increase in SMA positive vessels was also 
observed, whilst at a contralateral region where minimal DAPI/LacZ expression was 















































Figure 18A-O. Double immunolocalization using fluorescent antibodies against
vWF and SMA to detect blood vessel density.  Left column (A-E): FITC fluorescence 
of vWF expression from ischemic limb tissue of DMEM, myoblasts, Ad-Null 
transduced myoblasts, Ad-VEGF transduced myoblasts and Ad-Bicis transduced 
myoblasts treated groups. Middle column (F-J): Corresponding TRITC fluorescence of 
SMA expression from the respective treatment groups. Right column (K-O): FITC and 
TRITC overlayed fluorescence of vWF and SMA expression respectively. (200x 
magnifications) 





































































































Figure 18P. Capillary density quantitated from vWF positive vessels in different 
treatment groups. Capillary density was significantly highest in the Ad-Bicis Myo 
group (P<0.001 vs normal, DMEM, Ad-Null Myo and Myoblast groups. P=.009 vs Ad-
























Figure 18Q. Maturation index of blood vessels formed in different treatment
groups. Majority of the blood vessels in all groups appear mature, with no significant 














































































Figure 19. SMA immunohistochemical staining on tissue of Ad-Bicis transduced 
myoblasts treated group. A. Box region shows numerous SMA expression of newly 
formed small fine vessels at periphery of muscle fibers at 6 w after transplantation
(indicated by blue arrows in B), revealed by DAB substrate (X100). B. Enlarged area of


















































Figure 20. Colocalization of LacZ expressing donor myoblasts and SMA positive 
vessels in Ad-Bicis transduced myoblasts injected group. Top: Extensive LacZ 
expression in an ischemic area, 6 w after transplantation, was accompanied by a
corresponding increase in SMA positive vessels at site of graft. Bottom: In a
contralateral site, minimal LacZ expression was detected, with a corresponding low

















































Figure 21. Colocalization of LacZ expressing donor myoblasts and SMA positive
vessels in Ad-VEGF transduced myoblasts injected group.   
A. Confirmation on proportional degree of expression between LacZ expressing donor
myoblasts and SMA positive vessels at 6 weeks after transplantation, taken under low 
power microscopic field (60x magnification). B. Enlarged area of insert in A - minimal 
LacZ expression in an ischemic area was accompanied by a corresponding low number
of SMA positive vessels (200x magnification) C. Enlarged area of insert in A -
extensive LacZ expression was once again accompanied by a corresponding increase in
















































Figure 22. Colocalization of DAPI-labeled donor myoblasts and SMA positive 
vessels. At site of extensive DAPI-labeled donor myoblasts in a viable muscle region at
8 w after transplanation, increase in TRITC fluorescence of SMA positive vessels were 
also observed (100x magnification). 
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This suggested that increased in vessel density was induced by the overexpression of the 
exogenously introduced angiogenic growth factors from the donor myoblasts. 
 
3.6 In vivo secretion of VEGF and expression of myosin heavy chain 
Immunohistochemical staining for VEGF on LacZ positive tissue sections obtained 
from group-5 detected extensive expression of the angiogenic growth factor, both within 
the vicinity of the transplanted cells or in areas distal to it, in marked contrast to DMEM 
control group-1 which exhibit only faint VEGF signal (Figure 23). Similarly, myosin 
heavy chain expression was widespread within the transplanted region, both within the 










































































Ad-Bicis Myo/Transplant area 
DMEM Negative control 
Ad-Bicis Myo/Distal area 
Figure 23. VEGF immunohistochemical staining on LacZ positive tissue sections.
Top row: Extensive expression of VEGF demonstrated both within the vicinity of
transplanted cells (Left) or areas distal to it (Right, indicated by arrows) of Ad-Bicis 
transduced myoblasts group at 6 w after transplantation. (200x magnifications) Bottom
row: Faint or no VEGF signal from DMEM injected group, 6 w post-treatment (Left) 
















































Myosin/Rhodamine+DAPI - Viable 
Myosin/DAB+LacZ - Ischemic 
Figure 24. Myosin immunohistochemical staining in transplant area. Myosin heavy 
chain expression was widespread within the transplant region. Top: Rhodamine 
fluorescence of myosin heavy chain from viable muscle fibers of a group-4 animal at 6 
w after transplantation, colocalized with DAPI-labeled donor myoblasts (150x 
magnification). Middle: Rhodamine fluorescence of myosin heavy chain in ischemic 
area also colocalized with DAPI-labeled donor myoblasts in a group-5 animal at 6 w 
after transplantation (100x magnification). Bottom: Further confirmation from extensive 
myosin heavy chain expression (revealed by DAB substrate) in region of LacZ 
expressing donor myoblasts of a group-5 animal at 6 w after transplantation (200x 
magnification). 
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4   DISCUSSION 
 
Therapeutic angiogenesis for improvement of peripheral blood flow has been a 
subject of intense research interest. Both preclinical and clinical studies have been 
reported in the literature using several treatment modalities for application in PVD (Table 
3 and 4). In the former, various angiogenic growth factors have been used in animal 
models of lower limb ischemia including VEGF, aFGF, bFGF, PDGF, Ang-1 and nitric 
oxide, together with different routes of administration and various methods to measure 
the treatment outcome. In the clinical trials, studies ranging from uncontrolled case 
reports to larger randomized controlled trials, using several different treatment modalities 
as previously mentioned, have also been reported. Other than the use of different 
treatment modalities, patient selection criteria and endpoint measurement, as well as 
different study designs and duration of therapy have been employed. As such, meaningful 
comparisons on the treatment efficacy are often difficult. There is no doubt that much 
still needs to be learnt about the optimum treatment modality, dosage and route of 
administration. However, it is now becoming clear that relying on single growth factor 
protein or its gene administration is insufficient for the development of a functional 
vascular system and can cause serious complications (Carmeliet, 2000b; Lee et al., 2000; 
Celletti et al., 2001; Epstein et al., 2001). These complications are caused mainly by the 
instability and leakiness of the newly formed vascular networks. There is compelling 
evidence which suggests that the complex angiogenic process requires more than a single 
growth factor, involving interplay between various anti- and pro-angiogenic growth 
factors, and their receptors (Folkman and D'Amore, 1996; Risau, 1997; Carmeliet, 2000a). 
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In view of these previous reports, more recent studies have focused on the use of 
combination of factors or their genes. Notably, the synergistic interaction between 
VEGF165 and Ang-1 to produce functional and leakage-resistant neovascularization has 
been the very reason for their suitability in combination as a promising and safe option 
for therapeutic angiogenesis. Combining the synergistic effect between VEGF165 and 
Ang-1 together with myoblast therapy for treatment of ischemic limb disease would have 
the additional advantage of inducing myogenesis on top of the commonly reported 
angiogenesis in ischemic limbs. The aim of the present study was to deliver both 
VEGF165 and Ang-1 genes in a single administration using a novel bicistronic adenoviral 
vector that was carried in skeletal myoblasts, to achieve angiomyogenesis to improve 
overall performance of ischemically damaged hind limb in a rabbit model.  
 
4.1 Skeletal myoblasts purification and culture 
In order to achieve these objectives, autologous primary skeletal myoblasts isolated 
directly from adult rabbit skeletal muscle tissue were used. The reason being that primary 
skeletal myoblasts more closely approximate myogenesis and do not form tumours in 
vivo, in marked contrast to established myogenic cell lines such as C2C12 (Rando et al., 
1994). Established protocols for the isolation and expansion of primary skeletal 
myoblasts from animal and human skeletal muscles (Rando et al., 1994) now make it 
possible for skeletal myoblasts to be taken full cycle from the animal to the culture dish 
and back to the animal. However, the non-myogenic contaminant population of 
fibroblasts in a primary muscle culture can complicate the results and hence, jeopardize 
the success of the approach. In fact, presence of these fibroblasts in the transplanted cell 
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population may persist in the muscle interstitium to produce adverse effects such as 
increased interstitial connective tissue that will decrease contractility power of the limb. 
During the present study, this was overcome by enriching the purity of skeletal myoblasts 
population isolated using modified culture conditions combined with conventional 
preplating technique. Initial period of skeletal myoblasts culture made use of a patented 
optimized culture medium (Cell Transplants Singapore Pte. Ltd.). This preferentially 
supported the growth of skeletal myoblasts relative to fibroblasts. Parallel to this, 
preplating exploits the differential adhesion characteristics of skeletal myoblasts and 
fibroblasts (Blanco-Bose et al., 2001). As the latter adhere to tissue culture dishes with 
greater avidity than skeletal myoblasts, freshly isolated mixed population of cells could 
be enriched for skeletal myoblasts by preplating the culture on a dish and collecting the 
cells that have not adhered after 1 h, and transferring them to fresh culture dishes. 
Apparently, the purity of skeletal myoblast population is enhanced with increased number 
of preplatings performed (Qu et al., 2000; Qu-Petersen et al., 2002). Some of the skeletal 
muscle-specific markers such as the transcription factors MyoD, Myf5, myogenin, 
specific actins or myosins have been used to assess the purity of skeletal myoblasts. 
However, besides these markers, desmin expression is considered to be more superior as 
it provides information regarding the ability of skeletal myoblasts to undergo fusion to 
form multinucleated myotubes. We assessed the purity of skeletal myoblasts in the 
population of muscle-derived cells by staining the cells for desmin expression. More than 
75 to 80 % of the culture skeletal myoblasts stained positive for this myogenic marker. 
Formation of multinucleated myotubes had been observed in this study when myoblast 
culture was allowed to grow at high density and in low serum culture conditions. The 
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high positive desmin expression in the skeletal myoblasts culture gave an early head start 
as it is also generally accepted that skeletal myoblasts expressing richer levels of desmin 
show better survival and stability in the host tissue. Skeletal myoblasts of low passage 
number were used as they are less prone to senescence or transformation. Indeed, it has 
been demonstrated by others that passage of primary mouse skeletal myoblasts beyond 35 
to 40 doublings lead to their spontaneous transformation into immortalized cells which 
continue to proliferate when implanted in vivo (Irintchev et al., 1998; Lu et al., 2001).  
These early passage cells were transduced with adenoviral bicistronic vector 
encoding for both VEGF165 and Ang-1. Double fluorescent immunostaining revealed that 
more than 75 to 80 % of the cells simultaneously expressed both the growth factors. It 
was noted, however, that the intensity of fluorescent signals for Ang-1 was relatively 
weaker as compared to VEGF165 signals. The difference in expression level of the two 
growth factors may be attributed to their different position with respect to the promoter 
region that controlled their expression. As shown in Figure 25, VEGF165 gene was 
located immediately downstream of the murine cytomegalovirus (MCMV) immediate 
early gene 1 enhancer/promoter whereas that of Ang-1 is much further away, beyond the 
VEGF165 and internal ribosome entry site (IRES) sequence. As such, it was likely that the 
longer distance between the promoter and Ang-1 decreased its basal expression level, and 












Figure 25. Schematic diagram of recombinant adenovirus expressing VEGF165 and 
Ang-1. (IRES = Internal ribosome entry site; SV 40 = Simian virus 40 polyadenylation 
signal). 
 
4.2 Animal model development 
Ten days prior to implantation, the rabbit model of hind limb ischemia was created 
by multiple ligatures of the femoral artery. Given the critical importance of such animal 
models of hind limb ischemia in our understanding of peripheral vascular disease and 
evaluating therapeutic strategies to improve peripheral circulation, it is imperative that 
these models closely simulate the human ischemic disease. Unfortunately, the preparation 
of an animal model of the ischemic limb that is comparable with chronic human ischemia 
remains a daunting task. The problem is compounded by the remarkable ability in the 
animals to develop collaterals. It seems that the simple ligation of one or two iliac or 
femoral arteries could not produce adequate ischemia at rest (Janda et al., 1974; 
Urbanova et al., 1974; Seifert et al., 1985; Challiss et al., 1986; Hendricks et al., 1990). In 
this regard, the present study engaged the use of eight-point permanent ligation of the 



























pJM17 vector backbone 
(details not shown) 
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addition, contrary to most other studies who excised a substantial part of the femoral 
artery (Pu et al., 1993; Asahara et al., 1995; Takeshita et al., 1996; Gowdak et al., 2000a; 
Masaki et al., 2002; Hershey et al., 2003), we chose only to occlude a short sequence of 
this vessel that was sufficiently long to avoid simple jumping of collaterals across the 
ligature (Bauters et al., 1994; Takeshita et al., 1994b, 1995) in order to make it clinically 
more relevant and with similarity to the natural obliterative disease process. Nonetheless, 
even with such multiple ligatures, collaterals were still observed at 10 d post-operation 
(as captured by baseline angiograms). The developing collaterals in the rabbit hind limb 
after femoral artery occlusion only compensate up to 30 % of the normal maximal flow 
(Schaper et al., 1976), thus leaving ample room for therapeutic improvement. The rabbit 
model was chosen as our experimental animal due to its relatively cost effectiveness, easy 
maintenance, more reliable outcomes of functional studies and less complete formation of 
collaterals than the dog. 
 
4.3 Skeletal myoblast transplantation and survival of donor cells 
Similar to previous studies (Chae et al., 2000), skeletal myoblast transplantation 
was carried out 10 d after induction of hind limb ischemia to allow for postoperative 
recovery of animals and to allow the inflammatory response to recede. Inflammation 
plays an important role in the response to acute ischemia in this model system. Paoni et al. 
(2002) showed, by histological examination, that immune cell infiltration peaked at 3 d 
following induction of ischemia and this correlates well with the peak in gene expression 
of transcripts associated to neutrophils, macrophages, T and B cells. It was also 
demonstrated that the receptor transcripts for members of most of the major families of 
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immune cytokines were also induced at this time period. As such, the immediate 
transplantation of cells into such environment with ongoing inflammatory response 
following surgical trauma has adverse effects on the survival of the transplanted cells. 
This is illustrated by Zhang et al. (2001) who observed that transplantation of 
cardiomyocytes into a vascularized granulation tissue doubles the cell survival compared 
with injections made into an acutely necrotic cryoinjured myocardium. Besides avoiding 
the inflammatory response, the 10-d period allowance for skeletal myoblast 
transplantation was also engaged to allow development of endogenous collateral vessels.  
Studies done up to 90 d post femoral artery ligation have shown no significant collateral 
vessel augmentation beyond this 10-d period (Pu et al., 1994) and as such, justify the 
necessity for therapeutic improvement in vascularization even at this time point.  
Following myoblast transplantation, administration of the immunosuppressant 
cyclosporine and antibiotic cephalexin was carried out. The rationale behind these steps 
took into consideration previous reports that showed that intramuscular injection of 
cultured isolated skeletal myoblasts in classical myoblast transfer therapy resulted in 
massive and rapid necrosis of these donor cells despite their being autologous, with over 
90 % dead within the first hour after injection (reviewed in Beauchamp et al., 1999; 
Hodgetts et al., 2000; Skuk et al., 2000; Smythe et al., 2000c, 2001b). This rapid skeletal 
myoblasts death appears to be due to exposure to tissue culture conditions (Smythe et al., 
2000b) that apparently alter the surface antigenic characterisitics of skeletal myoblasts. 
Attachment of cells to culture vessel substrate and expansion in growth factors may result 
in loss or gain of surface receptors (Pouzet et al., 2000). Furthermore, long-term culture 
of the donor skeletal myoblasts for expansion in vitro may allow the animal proteins from 
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the growth medium to settle down and fix on the suface of the cells and alter their 
antigenic characteristics. As a consequence, transplantation of these skeletal myoblasts 
with altered antigenic characterisitics may provoke an acute host immune response in 
vivo which seemed to involve an early nonspecific inflammatory reaction (Grounds 1996; 
Guerrette et al., 1997a, b) as well as a later, specific cell-mediated immune response 
(Huard et al., 1994b; Kinoshita et al., 1996a; Guerrette et al., 1997a). To minimize death 
by immune rejection, transient administration of the immunosuppressant was therefore 
used. Unfortunately, immunosuppression of the host may affect the behaviour of the 
transplanted skeletal myoblasts. Apparently, altering the immunologic state of the host 
could potentially affect the fusion of transplanted myoblasts (Watt, 1982; Hardiman et al., 
1993). Furthermore, immunosuppressive agents are feared to have direct toxic effects on 
host muscle (Le Quintrec et al., 1991). In the light of these reports, immunosuppressant 
was administered only for a limited time, at the initial phase immediately after cell 
transplantation.  
The success of skeletal myoblast transplantation can generally be determined by a 
number of measures, including the percentage of skeletal myoblasts that fuse, the number 
of hybrid myofibers that are formed or the level of transgene expression. Hybrid 
myofiber formation is critical to efficient systemic delivery of recombinant proteins by 
the transplanted, genetically engineered myoblasts. Moreover, the ability to detect such 
hybrid fibers and being able to distinguish them from host fibers that have not been 
incorporated with donor cells allows for the assessment of the efficacy of myoblast 
transplantation. In this study, retroviral vectors carrying the nuclear localized nlsLacZ 
reporter gene was used to transduce myoblasts as a means of marking these donor cells. 
92 
Unlike adenoviral vectors which do not integrate into host chromosome, retroviral 
vectors allow integration of the LacZ gene into the transduced myoblast genome. As 
such, progeny of skeletal myoblasts that arise after multiple divisions and propagation, 
would still retain their LacZ tag without any dilutional effect. Detection of such β-
galactosidase activity by X-gal staining in a host myofiber would indicate the survival 
and engraftment of the donor cells. Long term nuclear expression of LacZ allowed us to 
study and follow the fate of the donor skeletal myoblasts in the host tissue and provided 
clear evidence of donor cell survival and formation of hybrid fibers as observed by the 
intermingling of the green nlsLacZ-expressing donor nuclei and hematoxylin-stained 
purple host nuclei (Figure 11). These can be easily distinguished from fibers of the host 
origin indicated by the presence of only non-LacZ expressing host purple nuclei (Figure 
11) (Barr et al., 1991; Dhawan et al., 1991). Moreover, it also allowed assessment of the 
engraftment, survival and long-term fate of the myoblasts after transplantation. However, 
since retroviral transduction efficiency of skeletal myoblasts achieved with nlsLacZ gene 
was less than 100 %, the cells were addititonally labeled with BrdU and DAPI for post 
transplant identification. 
 
4.4 Formation of heterokaryons 
The donor skeletal myoblasts survived adequately in vivo for ≥ 6 w of our 
observation as assessed by extensive X-gal staining, and confirmed by 
immunohistochemical staining for BrdU and DAPI fluorescence. Similar to the previous 
findings (Rando et al., 1995; Smythe et al., 2000a), the fate of our implanted skeletal 
myoblasts was either fusion with the host muscle fibers, fusion with regenerating muscle 
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cells of the host, fusion with other implanted myoblasts, or remaining quiescent as 
mononucleated cells or death. This observation further supports existing evidence that 
satellite cells are heterogenous in nature (Schultz et al., 1994; Rantanen et al., 1995; 
Molnar et al., 1996) with at least two populations  fusing and non-fusing isolated 
from skeletal muscle of various species to date (Baroffio et al., 1996). Although we do 
not know the extent of cell death among the implanted population, the predominant fate 
of surviving cells was either fusion to mature host fibers as detected by extensive DAPI-
labeled donor nuclei or persistence as β-galactosidase/DAPI labeled mononucleated cells 
at the site of ischemic region. The possibility of false positive DAPI signals due to DAPI 
leaking to neighbouring cells or being released upon cell death is very unlikely. 
Thompson et al. (2003) has shown that injection of lysed DAPI-labeled cells showed no 
uptake of the dye at 7d post-injection. As for accumulation of donor cells at the site of 
ischemic region, this is not surprising since it has been demonstrated that at sites of 
skeletal muscle injury, chemotactic growth factors are produced and these significantly 
enhanced myoblasts migration to the injured region (Chen and Quinn 1992; Kurek et al. 
1996; Bower et al. 1997). Furthermore, there is a strong possibility that fragmentation of 
the extracellular matrix caused by muscle injury (Morgan et al. 1990, 1993) as in the 
ischemic area, promotes myoblasts migration compared to the intact matrix in uninjured 
skeletal muscle.  
The resultant hybrid or new myofibers act as platforms for secretion of the 
exogenously introduced angiogenic growth factors VEGF165 and Ang-1. To our 
knowledge, this is the first study using a bicistronic vector for simultaneous co-
expression of the two transgenes VEGF165 and Ang-1 in the ischemic limb. Unlike 
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previous studies which involved two monocistronic vectors to co-administer their 
combination of growth factor genes (Arsic et al., 2003), utilizing a bicistronic vector 
provided a less cumbersome delivery option by simplifying the construct design and 
allowing delivery of the two transgenes in a single administration. Because the vector 
carries genes that encode for secreted proteins, as opposed to proteins that remain 
intracellularly, this may yield meaningful biologic outcomes because of the paracrine 
effects of the secreted gene products. Indeed, in vivo secretion of the growth factor was 
demonstrated in this study by its extensive expression, both within the vicinity of the 
transplanted cells or in areas distal to it (Figure 23). As such, even when the number of 
successfully Ad-Bicis transduced skeletal myoblasts implanted had been low, they should 
still exert a reasonable level of enhanced angiogenesis in the ischemic limb. The secreted 
angiogenic growth factors give the additional advantage of improved graft survival since 
they contribute to improved blood supply through both vasodilatation and enhanced 
angiogenesis. This notion was supported in a recent study by Germani et al. (2003) who 
demonstrated that VEGF administration to differentiating C2C12 skeletal myoblasts 
prevented apoptosis, while inhibition of VEGF signaling either with selective VEGF 
receptor inhibitors or a neutralizing Flk-1 antibody, enhanced cell death approximately by 
3.5-fold. Hence, this result points to the supportive role of VEGF in donor skeletal 
myoblast survival. This is particularly beneficial in the early stage after cell 
transplantation, when the grafted cells are more prone to the various pathological 
processes caused by environmental stress such as the ischemic condition of the limb as 
well as mechanical injury implicated during the cell injection procedure.  
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4.5 Blood vessel density analysis 
The bioactivity of the released angiogenic growth factors was confirmed by 
increased vascularization detected in the ischemic hind limbs of animals that received 
Ad-Bicis transduced skeletal myoblast transplantation (group-5) as compared to animals 
from other groups. This was observed by angiograms that capture radiographically visible 
collaterals and histological sections immunostained for von Willebrand Factor VIII (vWF) 
and smooth muscle actin (SMA) to detect the finer capillary networks. Formation of the 
finer capillary network was an expected outcome of the short term VEGF overexpression, 
given the very well known stimulating properties of VEGF on endothelial cell 
proliferation and migration to induce capillary sprouting (Neufield et al., 1999). The 
combined delivery of VEGF and Ang-1 showed remarkably large proportion of the 
vessels coated with smooth muscle layer (Figure 18J). These observations were in perfect 
agreement with the results from previously documented studies showing that Ang-1 was 
a maturation factor essential for the formation and development of stable, non-leaky 
vessels (Thurston et al., 2000). We also investigated whether there is a possibility that 
increase in vessel number was coincidentally due to angiogenesis involved in 
inflammatory response to granulation tissue, contrary to the underlying treatment 
received. Tissue sections positive for LacZ expressing or DAPI-labeled donor myoblasts 
(thus indicating the transplanted region) were counterstained with SMA to visualize 
functional neovascularization. The result showed that enhanced neovascularization 
coincides well with regions where there are transplanted cells, be it in tissue area where 
viable mature muscles were encountered or in areas where ischemically damaged fibers 
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were observed. This suggests that increased in blood vessel density was genuinely the 
result of Ad-Bicis transduced myoblasts treatment.  
Similar results were observed in group-4 animals as well which displayed a large 
proportion of vessels positive for the smooth muscle coat. This is intriguing since 
previous findings have led to the prevalent theory that VEGF administration alone 
induced formation of merely immature capillaries (Baumgartner et al., 1998; Thurston et 
al., 1999; Baumgartner, 2000; Thurston et al., 2000; Masaki et al., 2002; Ozawa et al., 
2004). Nonetheless, a variety of animal studies have also made it clear that the 
physiological response to VEGF is complex and can vary depending on the target tissue, 
mode of delivery and dosage (Bauters et al., 1995; Springer et al., 1998; Lu et al., 2001; 
Masaki et al., 2002; Arsic et al., 2003). It is reasonable to speculate the difference in our 
results to myoblast-mediated gene transfer biology and dosage of VEGF delivered. In a 
study by Ozawa et al. (2004), it was demonstrated that there exists a discrete threshold 
level in VEGF dosage (~70ng/106 cells/day), below which normal, non-leaky, stable 
capillaries were induced and above which hemangioma growth occurs. Thus, long-term 
continuous delivery of VEGF, when maintained below a threshold microenvironmental 
level, can lead to normal angiogenesis without other exogenous growth factors. On the 
other hand, overexpression of VEGF above this threshold level, without the 
accompaniment of maturation signals, leads to aberrant angiogenesis. In the present 
study, the level of VEGF expressed from Ad-VEGF transduced myoblasts could have 
been below that of this threshold level in which aberrant angiogenesis would have 
occurred. It must be highlighted that although Ad-VEGF and Ad-Bicis are both derived 
from human adenovirus type 5, there is a slight difference in the promoter construct of 
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these two viruses. Whilst expression of VEGF from Ad-VEGF was driven by the 
relatively weaker human cytomegalovirus (CMV) immediate early gene 1 
enhancer/promoter, VEGF and Ang-1 genes in the Ad-Bicis are driven by the stronger 
murine CMV (MCMV).  Indeed this was reflected in the ELISA result that showed 
higher peak level of VEGF secretion from the Ad-Bicis transduced myoblasts 
(35.04±1.91 ng/mL - when collected from medium conditioned over 2 d with 105 cells 
seeded; or 175.2 ng/mL/106cells/day) compared to that of Ad-VEGF transduced 
myoblasts whose peak VEGF expression was only 19.52±4.12 ng/mL (when collected 
from medium conditioned over 2 d with 105 cells seeded; or 97.6 ng/mL/106cells/day). In 
this case, the lower level of exogenously introduced VEGF from the Ad-VEGF 
transduced myoblasts merely acted as an initiator to kick off the angiogenic cascade that 
recruited other endogenous members involved in the process to eventually form mature 
blood vessels. However, if in any case the level of VEGF expressed from the myoblast 
transduced with the Ad-VEGF was above the threshold level, the lack of numerous 
immature vessels observed could be attributed to myoblast-mediated gene transfer 
biology. Expressing VEGF165 from a myoblast platform possibly involved secretion of 
other cytokines from the skeletal myoblasts as well which may be responsible for the 
vessel maturation observed. Indeed, studies have reported the expression of platelet 
derived growth factor (Sejersen et al. 1986) and epidermal growth factor-like protein 
(Chen et al. 1995) from myoblasts, both of which play a substantial role in stabilization 
of newly formed blood vessels (Yancopoulos et al. 2000; Ferrara 2002; Senger et al. 
1983; Shing et al. 1984). Besides, recent investigations also support the notion that 
VEGF-activated endothelial cells may in turn result in the release of other cytokines to 
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initiate the cascade of events leading to eventual vessel maturation (Yancopoulos et al., 
2000). Furthermore, extensive vessel maturation was also observed in animals from 
groups-2 and -3, as calculated from their maturation index. Taken together, these data 
supported the suggestion that skeletal myoblasts themselves secrete angiogenic growth 
factors that contribute to maturation of newly formed blood vessels. Nonetheless, the 
basal expression of these growth factors from myoblasts are minimal. It is therefore still 
important that overexpression of exogenously introduced VEGF beyond the threshold 
level should be accompanied by overexpression of maturation factors such as Ang-1 to 
circumvent imbalance of angiogenic signals. It would be interesting if an additional 
control group receiving merely the adenoviral vector carrying VEGF had been included 
in this study as well. Unless this was done, it would remain difficult to claim the stated 
hypothesis of cytokine secretion by myoblasts. Nonetheless, a similar study by Hershey 
et al. (2003) demonstrated that intramuscular injection of Ad-VEGF165 into the ischemic 
limb of rabbit model led to an increase in capillary density but not an increase to the 
growth and development of those larger conduit vessels. In fact, Ad-VEGF165 
administered at high dose even caused hind limb edema. This study, in comparison to 
ours, therefore provides some insights to differences between myoblast-mediated gene 
transfer and direct viral vector gene transfer biology. 
More importantly though, despite displaying similar maturation index across all 
groups, group-5 still sustained the highest blood vessel density count. This was in perfect 
agreement to previous studies reporting higher capillary density in rabbit ischemic hind 
limbs that received combined VEGF and Ang-1 administration as compared to those 
receiving either only VEGF or Ang-1 alone (Chae et al., 2000; Arsic et al., 2003; Shyu et 
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al., 2003a). The results of this study underlined the notion that synergistic interaction 
between VEGF165, Ang-1 and cytokines released from skeletal myoblasts provided the 
optimal cocktail of angiogenic growth factors essential for enhanced functional 
neovascularization. Though the physiological consequences of such increased vessel 
density were not assessed in this study, it seemed plausible that the increased 
microvascular capacity should, for a similar level of blood flow, allow better oxygen 
extraction by the ischemic muscles and consequently, better muscle performance.  
Angiographic evidence of improved arteriogenesis in group-5 further supported the 
enhanced neovascularization detected by immunohistochemistry for vWF and SMA. 
Although there was no statistically significant difference among groups-3, -4, and -5, 
more collaterals were formed in the order of group-5 > group-4 > group-3. Moreover, 
angiographic score comparison between group-5 versus the groups-2 and -3 revealed 
significant improvement in group-5. This result is of pivotal interest since from a 
therapeutic point of view, it is the growth and development of the larger conduit vessels 
(as captured by angiography) that is most likely to impart functional improvement by 
reducing vascular resistance imposed by the occluded vessel in an ischemic area through 
restoration of blood flow to the underperfused areas at risk for necrosis or loss of 
function. The angiographic score result was inconsistent with capillary density. Wherelse 
capillary density clearly showed a marked difference between group-5 as compared to all 
the other groups, such a difference was not as significant when reflected at the 
angiographic level. This slight discrepancy may be attributed to the different sensitivity 
and specificity of the two techniques used. Whilst histological study on vascular density 
allows for detection of small vessels such as capillaries and arterioles of less than 40 µm 
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in diameter, the resolution of the angiographic apparatus is less sensitive and precludes 
the visualization of vessels less than 200 µm in diameter (Mori et al., 1994; Takeshita et 
al., 1997). Perhaps, the size of arterioles that reflect the significant difference between 
groups-5, -4, and -3 were too small to permit angiographic detection of the newly formed 
vascular network. However, it must also be emphasized that we only measured 
arteriogenesis, but not signs of improvement to the previously underperfused tissue. 
Studies using biochemical markers of impaired blood supply will further elucidate 
whether the lower leg was still ischemic or has truly improved in their blood supply. 
The use of adenovirus in this study is justified by its transient expression of the 
transgenes. Unlike retroviral vector that is stably integrated into the host genome, 
adenovirus remains outside the genome as an episome, and as such result in progressive 
loss of the transgene expression. This is desirable as long-term stable expression of the 
angiogenic growth factor genes often results in deleterious effects such as hemangiomas 
(Springer et al., 1998; Lee et al., 2000). The transient expression of VEGF secreted from 
our Ad-Bicis transduced myoblasts was confirmed by ELISA and it clearly showed a 
single peak expression at 6 d post transduction, thereafter dwindling progressively to an 
insignificant value by 28 d post transduction. However, despite in vitro data showing 
cessation of VEGF overexpression beyond 28 d, we still observed extensive in vivo 
VEGF expression in Ad-Bicis transduced myoblasts transplanted group at 6 w after 
transplantation (Figure 23). This discrepancy could be attributed to the fact that the in 
vivo expression of these angiogenic growth factors are complex and can vary depending 
on the target tissue, mode of delivery and dosage (Bauters et al., 1995; Springer et al., 
1998; Lu et al., 2001; Masaki et al., 2002; Arsic et al., 2003). For instance, the 
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proliferative rate of myoblasts transduced with the Ad-Bicis within the three-dimensional, 
compact environment of a limb tissue might be slower than when these cells were 
allowed to be propagated on the two-dimensional growth surface of culture dishes that 
apparently have much more growth space for cell expansion. As such, in comparison to 
those cells grown in vitro, the slower-cycling nature of these transplanted cells would 
lead to their Ad episome being retained for a longer period of time before undergoing 
dilutional effect and thus progressive loss of the transgene expression. This may explain 
why extensive in vivo VEGF expression in Ad-Bicis transduced myoblasts transplanted 
group was observed even at 6 w after transplantation. 
Despite eventual progressive loss of the transgene expression in vivo, numerous 
mature blood vessels in the Ad-Bicis transduced myoblasts group was demonstrated even 
up to 8 w post-transplantation. Continuous VEGF supplementation is instrumental in 
preventing the apoptosis of vascular endothelial cells in immature blood vessels to 
maintain their viability (Alon et al. 1995). Upon maturation though, VEGF is no longer 
required for their survival (Benjamin et al. 1999). As such, this accounts for the relatively 
long-term maintenance of the mature blood vessels observed in the Ad-Bicis transduced 
myoblasts group. Hence, this is in line with the long term requirement for treatment of 
true severe chronic limb ischemia patients. 
 
4.6 Skeletal myoblasts as carriers of the angiogenic genes 
Another important difference in this study compared to others lies in the use of 
skeletal myoblasts as carriers of the bicistronic adenoviral vector. To date, the use of 
direct viral vector based gene delivery has remained questionable due to its serious 
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immunologic concerns. Adverse reactions from incomplete inactivation of the viral 
replication machinery may lead to life-threatening systemic inflammatory-like reactions 
(Leiden, 2000; Verma, 2000).  Furthermore, it has been reported that administration of 
adenoviral vectors immediately after induction of acute ischemia in rat hind limbs caused 
inflammation and subsequent limb gangrene that seemed to be aggravated by the 
adenovirus capsid protein (Brevetti et al., 2001). As such, this justifies our rationale for 
using myoblast-mediated gene delivery as a safe and promising protocol for gene 
therapy. Furthermore, the Ad-Bicis transduced myoblasts can be fully characterized in 
vitro before transplantation to ensure that the expression of the growth factors are of the 
correct size and function at pharmacologically useful levels. On the contrary, direct viral 
vector mediated gene transfer is often limited by the variability in the number of 
endogenous cells that take up and express the foreign gene. Besides, utilizing skeletal 
myoblasts as carriers of the bicistronic vector has the additional advantage of contributing 
to myogenesis for repair and repopulating of the traumatized muscle due to the ischemic 
damage. As documented by others and confirmed in this study (Figure 11-13), 
intramuscularly injected myoblasts are capable of fusing with pre-exisitng muscle fibers 
as well as with one another. In the resulting heterokaryotic muscle fibers, the donor 
nuclei are expected to supplement the lost genes in the host nuclei due to the ischemic 
injury. Moreover, being precursors of skeletal muscle, this fusion process should result in 
augmentation of the number of contractile elements in the damaged host muscle, possibly 
even resurrecting some surviving host cells in the necrotic region. Indeed, we observed 
extensive expression of skeletal muscle myosin heavy chain within the vicinity of LacZ-
expressing or DAPI-labeled donor skeletal myoblasts (Figure 24), suggestive of possible 
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neomyogenesis at the site of the cell graft from the donor skeletal myoblasts-mediated 
induction of myoblasts differentiation into skeletal muscle fiber to repopulate the 
ischemic area where muscle fiber disintegration occurred.  
 
4.7 Conclusions and future directions 
In conclusion, ex vivo angiogenic growth factor gene delivery by myoblast-
mediated transfer offers a potent option for therapeutic angiogenesis in limb ischemia. 
Our study gave evidence that concerted action amongst VEGF, Ang-1 and possibly 
cytokines released from myoblasts is capable of inducing enhanced functional 
neovascularization. Combined with the therapeutic myogenesis effect contributed by the 
myoblasts themselves, angiomyogenesis utilizing the duo combination of myoblast and 
angiogenic growth factor genes is an emerging therapeutic target for patients suffering 
from PVD. 
It is therefore of high priority to establish the safety of this treatment strategy. 
Future direction should take into consideration employing larger numbers of animals as 
well as using larger animal models such as porcines that are more physiologically similar 
to the human body to ascertain its safety issue. In addition, in line with treatment of true 
severe chronic limb ischemia patients, the treatment period should be extended longer 
beyond the existing eight-week period. More interestingly, a different approach utilizing 
lipofection to deliver the angiogenic growth factor genes to the myoblasts rather than the 
current adenoviral mediated transduction could be employed to achieve an improved 
foolproof safety of the procedure.  
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Given the availability of resources, it is also of considerable interest that more 
functional studies to evaluate signs of improvement to the previously underperfused 
tissue be performed. This may include measuring the regional blood flow to limb muscles 
for any indication of improved perfusion in the ischemic region either by microspheres 
administration, SPECT-sestamibi scan or Doppler guidewire. Use of the more reliable 
transcutaneous oxygen and carbon dioxide pressure foot monitoring as a metabolic test of 
actual tissue perfusion could also be used to discriminate the severity of the limb 
ischemia before and after treatment. Indeed, this will further elucidate whether the lower 
leg is still ischemic or has truly improved in their blood supply. 
The increase in microvascular capacity should, for a similar level of blood flow, 
allow better oxygen extraction by the ischemic muscles and consequently lead to better 
muscle performance; not to mention the additional therapeutic myogenesis benefit from 
the myoblast transplantation itself. As such, besides assessing response to therapeutic 
angiogenesis, future study should also take into account of evaluating improvement to the 
muscle. One such study to assess improvement of the bioenergetic reserve of the muscle 
is the use of 31P nuclear magnetic resonance spectroscopy. Maximum twitch tension and 
tetanic tension should also be measured to assess force generation while fatigue index can 
be used as an indicator to assess the number of limbs that recovered. 
Despite the novelty of therapeutic angiomyogenesis in treatment of limb ishcemia, 
cautious optimism is warranted as the field progresses from benchwork to bedside. Our 
data may provide guidance for the ongoing clinical trials of angiogenic growth factors for 
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Publications, Posters & Invited Seminar Presentations 
 
• Autologous skeletal myoblasts transduced with a new adenoviral bicistronic 
vector for treatment of hind limb ischemia. Muhammad I Niagara, Husnain Kh 
Haider, Lei Ye, Valerie SW Koh, Yean T Lim, Kian K Poh, Ruowen Ge, Eugene 
KW Sim. Journal of Vascular Surgery (In Press). 
• Therapeutic angiogenesis for treatment of peripheral vascular disease. Niagara M 
Idris, Husnain Kh Haider, Michelle WK Goh, Eugene KW Sim. Growth Factors 
(In press). 
• Oral presentation on Angiogenic synergy between VEGF and Angiopoietin-1 
together with myoblast therapy for the treatment of ischemically damaged hind 
limb. Niagara M Idris, Husnain Kh Haider, Yean Teng Lim, Kian Keong Poh, 
Ruowen Ge, Eugene KW Sim, American Heart Association Scientific Sessions 
2004, New Orleans, Louisiana, USA, Nov 7-10, 2004. 
• Represented Singapore Cardiac Society in the Young Investigator Award 
competition on Ex-vivo gene therapy using autologous myoblasts expressing 
VEGF and Angiopoietin-1 for the treatment of ischemically damaged limbs. 
Niagara MI, Haider KH, Ye L, Koh SW, Lim YT, Poh KK, Ge R, Sim EKW, 
15th ASEAN Congress of Cardiology, Pattaya, Thailand, Oct 2327, 2004. 
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• Poster presentation on Autologous Myoblasts Transduced With A Novel 
Bicistronic Adenoviral Vector Expressing VEGF And Angiopoietin-1 In A Rabbit 
Model of Hind Limb Ischemia. Niagara Muhammad Idris, Haider Khawaja 
Husnain, Ye Lei, Lim Yean Teng, Poh Kian Keong, Ge Ruowen, Sim Kwang Wei 
Eugene, National Healthcare Group (NHG) Annual Scientific Congress 2004, 
Raffles City Convention Centre, Singapore, Oct 9-11, 2004. 
• Poster presentation on Enhanced Neovascularization Using Autologous 
Myoblasts as Carriers of Vascular Endothelial Growth Factor and Angiopoietin-1 
in a Rabbit Model of Hindlimb Ischemia. Niagara Muhammad Idris, Haider 
Khawaja Husnain, Ye Lei, Lim Yean Teng, Poh Kian Keong, Ge Ruowen, Sim 
Kwang Wei Eugene, 8th National University of Singapore-National University 
Hospital Annual Scientific Meeting, Singapore, Oct 6-7, 2003. 
• Abstract on Autologous Myoblasts Transduced With A Novel Bicistronic Vector 
Expressing VEGF and Angiopoietin-1 in a Rabbit Model of Hind Limb Ischemia. 
Niagara M Idris, Husnain Kh Haider, Lei Ye, Shujia Jiang, Wei S Koh, Teng T 
Lim, Keong K Poh, Eugene KW Sim, accepted for oral presentation in the 3rd 
European Association for Cardio-Thoracic Surgery/European Society of Thoracic 
Surgeons Joint Meeting, Leipzig, Germany, Sep 12-15, 2004. 
• Oral presentation on Autologous myoblast transduced with a bicistronic vector 
encoding for human VEGF and Ang-1: A novel approach to treat ischemically 
damaged limbs. Niagara Muhammad Idris, Khawaja Husnain Haider, Ye Lei, 
Koh Seow Wei, Lim Yean Teng, Poh Kian Keong, Ge Ruowen, Eugene Sim 
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Kwang Wei, 5th Combined Annual Scientific Meeting Incorporating The 4th 
GSS-FOM Scientific Meeting, Clinical Research Centre, May 12-14, 2004. 
• Oral presentation on Angiogenic Synergism Between Human VEGF and 
Angiopoietin-1 Together With Cell Therapy for the Treatment of Ischemically 
Damaged Hind Limb. Niagara M Idris, Husnain Kh Haider, Koh S Wei, Lim Y 
Teng, Poh Kian Keong, Henry Chan, Ge Ruowen, Eugene EK Sim, 12th Annual 
Meeting of the Asian Society for Cardiovascular Surgery, Istanbul, Turkey, Apr 
19-22, 2004. 
• Young Investigator Award oral presentation on Ex-vivo gene therapy using 
autologous myoblasts expressing VEGF and Angiopoietin-1 for the treatment of 
ischemically damaged limb. Niagara MI, Haider KH, Ye L, Koh SW, Lim YT, 
Poh KK, Ge R, Sim EKW, Singapore Cardiac Society 16
th
 Annual Scientific 
Meeting, Ritz Carlton Millenia Singapore, Mar 21, 2004. 
• Oral presentation on Enhanced Neovascularization Using Autologous Myoblasts 
as Carriers of VEGF165 in a Rabbit Model of Hind Limb Ischemia. Niagara M 
Idris, Khawaja H Haider, Ye Lei, Shujia Jiang, Lim Y Teng, Poh K Keong, 
Terrance Chua, Peter K Law, Eugene KW Sim, 16th Biennial Congress of 
Association of Thoracic and Cardiovascular Surgeons of Asia, Bangkok, Thailand, 
Nov 16-19, 2003. 
• Poster presentation on Therapeutic Angiomyogenesis Using Autologous 
Myoblasts Carrying VEGF165 in a Rabbit Model of Hindlimb Ischaemia. 
Niagara Muhammad Idris, Khawaja Husnain Haider, Lei Ye, Shujia Jiang, 
Rufaihah Abdul Jalil, Yean Teng Lim, Kian Kong Poh, Terrance Chua, Peter K. 
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Law, Eugene Kwang Wei Sim, 7th National University of Singapore-National 
University Hospital Annual Scientific Meeting, Singapore, Oct 2-3, 2003. 
• Angiomyogenesis in a rodent heart using myoblasts carrying VEGF165. Ye Lei, 
Husnain Kh Haider, Jiang Shujia, Niagara M Idris, Rufaihah A Jalil, Peter K Law, 
Eugene KW Sim. International Journal of Medical Implants and Devices 2003; 1: 
100-155. 
• Myoblast therapy and angiogenesis: human myoblasts carrying human VEGF165 
for rehabilitation of injured heart. L Ye, Kh H Haider, SJ Jiang, LH Ling, N Muhd 
Idris, R Abd Jalil, PK Law, EKW Sim. 12th International Congress on 
Cardiovascular Pharmacotherapy, Barcelona, Spain, May 7-10, 2003. 
• Ex-vivo delivery hVEGF165 for improved myocardial function in porcine heart 
model of chronic infarction. Ye Lei, Haider Kh Husnain, Shujia Jiang, Niagara M 
Idris, Peter K Law, Salim Aziz, Chua T, Wong P, Sim EKW. 11th Annual 
Meeting of the Asian Society for Cardiovascular Surgery, Kuala Lumpur, 
Malaysia, Feb 12-15, 2003. 
 
 
 
